Dimension exclusion chromatography for characterizing host cell proteins

By combining size exclusion chromatography and liquid chromatography-mass spectrometry, optimized conditions were used to identify and remove HMW aggregates and HCPs in biotherapeutic products. This solved the problem of high molecular weight aggregates and host cell proteins in biotherapeutic products that are difficult to remove in existing technologies, thereby improving the safety and efficacy of the products.

CN118922720AInactive Publication Date: 2024-11-08REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027950.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-17
Filing Date
2023-02-24
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively identify, characterize, and remove high molecular weight (HMW) aggregates and host cell proteins (HCPs) in biotherapeutic products, which not only affects drug efficacy but also increases the risk of adverse immune responses in patients.

Method used

Size exclusion chromatography (SEC) was used as an orthogonal separation method, combined with liquid chromatography-mass spectrometry (LC-MS) analysis. Denaturation and digestion conditions were optimized, and HCP was identified and removed through SEC fractionation, surfactant inclusion, and acid precipitation.

Benefits of technology

This improves the safety and efficacy of biotherapy products by accurately identifying and removing HCPs from the HMW fraction, thus reducing the risk of immunogenicity and product instability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005044335160000411
    Figure BDA0005044335160000411
  • Figure BDA0005044335160000421
    Figure BDA0005044335160000421
  • Figure BDA0005044335160000431
    Figure BDA0005044335160000431
Patent Text Reader

Abstract

The present invention generally relates to methods of identifying and characterizing host cell proteins. In particular, the invention relates to the use of size exclusion chromatography under non-denatured or denatured conditions to enrich host cell proteins in a sample and characterize binding of host cell proteins to proteins of interest.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 314,144 filed on February 25, 2022, U.S. Provisional Patent Application No. 63 / 341,381 filed on May 12, 2022, and U.S. Provisional Patent Application No. 63 / 426,221 filed on November 17, 2022, each of which is incorporated herein by reference. Technical Field

[0003] The present application relates to methods for identifying, characterizing and removing host cell proteins. Background Art

[0004] High molecular weight (HMW) aggregates in biotherapeutic products pose challenges in drug development, commercial manufacturing, and product stability throughout the shelf life of the product. HMW aggregates may form during manufacturing, formulation, and shipment or delivery to patients. The presence of HMW aggregates in biotherapeutic products may affect drug efficacy and increase the risk of adverse immune responses in patients. Therefore, the levels of HMW species in biotherapeutic products are monitored as critical quality attributes.

[0005] Another potential mechanism for the adverse effects of HMW species in biotherapeutics is the presence of host cell proteins (HCPs). The presence of residual host cell proteins (HCPs) may cause potential safety risks and manufacturing problems for biopharmaceutical products. Since recombinant DNA technology has been widely used to produce biopharmaceutical products in host cells, it is necessary to remove impurities to obtain biopharmaceutical products with high purity. Before conducting clinical studies, any residual impurities after purification bioprocessing should be present at an acceptably low level. Specifically, residual HCPs derived from mammalian expression systems (e.g., Chinese hamster ovary (CHO) cells) may endanger product safety, quality and stability. Even trace amounts of specific HCPs may sometimes cause immunogenic responses or undesirable modifications. Therefore, it is necessary to monitor host cell proteins in drug products and during the manufacturing process.

[0006] HCPs may end up as the final drug substance through a variety of different pathways. For example, HCPs may bind to biotherapeutics, thereby preventing their removal during purification. Alternatively, HCPs may co-purify with biotherapeutics in an unbound state. Understanding the mechanisms of HCP contamination may aid in process development for preventing further contamination.

[0007] Most monoclonal antibody (mAb) purification techniques involve an initial affinity chromatography step (e.g., Protein A affinity chromatography) followed by several polishing steps. The presence of HCPs in the Protein A eluate is primarily due to interactions with the column resin / ligand or the mAb. HCPs retained after Protein A purification due to column resin interactions may be removed in subsequent polishing steps. However, HCPs associated with mAbs are difficult to remove and may escape from the purification process. Identification of co-eluting HCPs and understanding the above interaction mechanisms are critical for process development.

[0008] Identification of HCP impurities in biopharmaceutical products is challenging due to the wide dynamic range of protein concentrations in samples and the extremely high complexity. Specifically, the presence of at least one high-abundance protein or peptide in a sample (such as a therapeutic protein) can create technical barriers to the detection, identification, and quantification of very low-abundance proteins in the sample. In addition, the presence of HCPs in the HMW fraction of biotherapeutic products and the possible contribution of said HCPs to adverse effects such as instability or immunogenicity have not been extensively characterized.

[0009] Therefore, there is a need for methods and systems for identifying, characterizing, and removing host cell proteins from biotherapeutic products in a sensitive and specific manner. Summary of the invention

[0010] Developed a method for identifying HCP using size exclusion chromatography (SEC) as an orthogonal separation method before subjecting a sample containing a protein of interest to liquid chromatography-mass spectrometry (LC-MS) analysis. A sample containing a protein of interest and at least one HCP can be separated into, for example, a high molecular weight (HMW) fraction, a main fraction, a tail fraction, and / or a low molecular weight (LMW) fraction, wherein the protein of interest is present in an abundance much higher than the abundance of the at least one HCP. Biotherapeutics such as antibodies, antibody fusion proteins, receptors, or receptor fusion proteins can be much larger than HCPs and can be effectively separated from HCPs based on size. HCPs are enriched in fractions depleted of a high abundance of protein of interest, allowing LC-MS analysis to better identify HCPs. The present disclosure describes optimization of the SEC-based method for HCP identification, including exemplary optimized denaturation conditions, digestion conditions, protein loading, SEC fraction division, surfactant inclusion, and acid precipitation.

[0011] A method for characterizing the binding of HCP to a protein of interest using SEC has also been developed. It is very valuable to understand the binding properties of HCP to a protein of interest, such as to understand the mechanism of host cell protein contamination in a sample (e.g., a drug substance). HCPs bound to a protein of interest will elute earlier in SEC than unbound HCPs. Under mild denaturing conditions, such as in 20% acetonitrile, weak HCP binding to a protein of interest will disappear, and HCP will show a shift to a lower molecular weight SEC fraction compared to separation under non-denaturing conditions, while strong HCP binding to a protein of interest will be substantially unaffected. Under strong denaturing conditions, such as in 12mM sodium lauroyl sarcosine and 12mM sodium deoxycholate, all HCP bindings to a protein of interest may disappear effectively. By comparing the separation profiles of HCPs under non-denaturing conditions and denaturing conditions, the binding properties of HCPs to a protein of interest can be determined.

[0012] In addition, a method for identifying HCP impurities, quantifying HCP impurities and removing HCP impurities from samples of interest (e.g., biotherapeutic products) has been developed. Specifically, the disclosure demonstrates that relevant HCPs may be greatly enriched in the HMW fractions of the product due to specific interactions with aggregates or polymers of the proteins of interest contained in the biotherapeutic product. HCPs can be identified and quantified using SEC analysis of the biotherapeutic product, followed by analysis and comparison of the SEC fractions. For example, a drug substance (DS) can be subjected to native digestion, SEC analysis, fractionation of HMW fractions, monomer fractions, and LMW fractions, further sample preparation (e.g., denaturation, reduction, digestion, and alkylation) and liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis to identify HCPs enriched in the HMW fractions of the biotherapeutic product and quantify the HCPs. An overview of the HCPs present in each SEC fraction of the biotherapeutic product DS can be developed to determine whether the product can be improved by separating and removing the SEC fractions, such as by reducing the abundance of relevant HCP impurities. For example, this determination can be made based on the concentration and / or abundance of the HCP, the percentage of HCPs enriched in a particular SEC fraction, and the known risk of including a particular HCP in a biotherapeutic product. Based on this determination, the process for collecting and purifying a biotherapeutic product sample (e.g., DS) can be improved by adding a SEC step to remove the HMW fraction containing the enriched HCPs, thereby improving the safety and efficacy of the biotherapeutic product.

[0013] The present disclosure provides a method for identifying HCP impurities in a sample. In some exemplary embodiments, the method comprises: (a) subjecting a sample comprising at least one protein of interest and at least one HCP impurity to size exclusion chromatography (SEC) analysis to produce fractions; and (b) subjecting the fractions to LC-MS analysis to identify the at least one HCP impurity.

[0014] In one aspect, the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

[0015] In one aspect, the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg. In a specific aspect, the amount of protein loaded onto the SEC column is about 10 mg.

[0016] In one aspect, the mobile phase for the SEC analysis comprises about 10 mM phosphate and about 150 mM NaCl. In another aspect, the mobile phase for the SEC analysis is a denaturing mobile phase. In a further aspect, the mobile phase for the SEC analysis is a non-denaturing mobile phase.

[0017] In one aspect, the mobile phase for the SEC analysis comprises acetonitrile, optionally wherein the concentration of the acetonitrile is between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 10% v / v, about 15% v / v or about 20% v / v. In a specific aspect, the concentration of the acetonitrile is about 20% v / v.

[0018] In one aspect, the mobile phase for the SEC analysis includes at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 6mM and about 36mM, about 12mM or about 24mM. In a specific aspect, the at least one surfactant is a detergent. In a more specific aspect, the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate and a combination thereof. In a further specific aspect, the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is about 12mM, and the concentration of sodium lauroyl sarcosinate is about 12mM.

[0019] In one aspect, the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction. In a specific aspect, the fractions further include a tail fraction. In another specific aspect, the HMW fraction comprises an eluent between about 0.3 column volumes (CV) and about 5 milli-absorbance units (mAU). In a further specific aspect, the main fraction comprises an eluent between about 5mAU and about 40mAU. In yet another specific aspect, the tail fraction comprises an eluent between about 40mAU and about 10mAU or between about 40mAU and about 3mAU. In still another specific aspect, the LMW fraction comprises an eluent between about 10mAU and about 1.1CV or between about 3mAU and about 1.1CV.

[0020] In one aspect, the method further comprises subjecting the fraction to enzymatic digestion prior to the LC-MS analysis of step (b). In a specific aspect, the enzymatic digestion is limited digestion. In another specific aspect, the enzymatic digestion is carried out by contacting the fraction with trypsin. In a further specific aspect, the enzymatic digestion is carried out by contacting the fraction with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000 or about 1:2000. In still another specific aspect, for the HMW fraction, the enzyme to protein ratio is about 1:200. In another specific aspect, for the main fraction, the enzyme to protein ratio is about 1:2000. In a further specific aspect, for the tail fraction, the enzyme to protein ratio is about 1 :500. In yet another specific aspect, for the LMW fraction, the enzyme to protein ratio is about 1 :200.

[0021] In one aspect, the method further comprises subjecting the fraction to acid precipitation prior to the LC-MS analysis of step (b). In a specific aspect, the acid precipitation comprises contacting the fraction with about 1% trifluoroacetic acid.

[0022] In one aspect, the liquid chromatography of step (b) comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0023] In one aspect, the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

[0024] The present disclosure provides an additional method for identifying host cell protein (HCP) impurities in a sample. In some exemplary embodiments, the method comprises: (a) subjecting a sample comprising at least one protein of interest and at least one HCP impurity to size exclusion chromatography (SEC) analysis to produce a fraction, wherein the mobile phase for the SEC analysis comprises about 12 mM sodium lauroyl sarcosinate and about 12 mM sodium deoxycholate; (b) subjecting the fraction to acid precipitation to produce a detergent-depleted fraction, wherein the acid precipitation comprises contacting the fraction with about 1% trifluoroacetic acid; (c) subjecting the detergent-depleted fraction to buffer exchange to produce a buffer-exchanged fraction; (d) subjecting the buffer-exchanged fraction to limited digestion to produce a peptide digest, wherein the limited digestion comprises contacting the buffer-exchanged fraction with trypsin at an enzyme to substrate ratio of between about 1:200 and about 1:2000; and (e) subjecting the peptide digest to LC-MS analysis to identify the at least one HCP impurity.

[0025] In one aspect, the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

[0026] In one aspect, the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg. In a specific aspect, the amount of protein loaded onto the SEC column is about 10 mg.

[0027] In one aspect, the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction. In a specific aspect, the fractions further include a tail fraction. In another specific aspect, the HMW fraction comprises an eluent between about 0.3 column volumes (CV) and about 5 milli-absorbance units (mAU). In a further specific aspect, the main fraction comprises an eluent between about 5mAU and about 40mAU. In yet another specific aspect, the tail fraction comprises an eluent between about 40mAU and about 10mAU or between about 40mAU and about 3mAU. In still another specific aspect, the LMW fraction comprises an eluent between about 10mAU and about 1.1CV or between about 3mAU and about 1.1CV.

[0028] In one aspect, the liquid chromatography of step (e) comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0029] In one aspect, the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

[0030] The present disclosure also provides a method for characterizing the binding of HCP impurities to a protein of interest. In some exemplary embodiments, the method comprises: (a) obtaining a sample comprising a protein of interest and at least one HCP impurity; (b) subjecting the sample to size exclusion chromatography (SEC) analysis using a non-denaturing mobile phase to produce a native fraction; (c) subjecting the sample of (a) to SEC analysis using a denaturing mobile phase to produce a denatured fraction; (d) subjecting the native fraction and the denatured fraction to LC-MS analysis to produce a native separation profile and a denatured separation profile of the at least one HCP impurity; and (e) comparing the native separation profile with the denatured separation profile to characterize the binding of the at least one HCP impurity to the protein of interest.

[0031] In one aspect, the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

[0032] In one aspect, the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg. In a specific aspect, the amount of protein loaded onto the SEC column is about 10 mg.

[0033] In one aspect, the mobile phase used for the SEC analysis comprises about 10 mM phosphate and about 150 mM NaCl. In another aspect, the denaturing mobile phase is a mild denaturing mobile phase.

[0034] In one aspect, the denaturing mobile phase comprises acetonitrile, optionally wherein the concentration of the acetonitrile is between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 10% v / v, about 15% v / v or about 20% v / v. In a specific aspect, the concentration of the acetonitrile is about 20% v / v.

[0035] In one aspect, the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction. In a specific aspect, the fractions further include a tail fraction. In another specific aspect, the HMW fraction comprises an eluent between about 0.3 column volumes (CV) and about 5 milli-absorbance units (mAU). In a further specific aspect, the main fraction comprises an eluent between about 5mAU and about 40mAU. In yet another specific aspect, the tail fraction comprises an eluent between about 40mAU and about 10mAU or between about 40mAU and about 3mAU. In still another specific aspect, the LMW fraction comprises an eluent between about 10mAU and about 1.1CV or between about 3mAU and about 1.1CV.

[0036] In one aspect, the method further comprises subjecting the fraction to enzymatic digestion prior to the LC-MS analysis of step (d). In a specific aspect, the enzymatic digestion is limited digestion. In another specific aspect, the enzymatic digestion is carried out by contacting the fraction with trypsin. In a further specific aspect, the enzymatic digestion is carried out by contacting the fraction with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000 or about 1:2000. In still another specific aspect, for the HMW fraction, the enzyme to protein ratio is about 1:200. In another specific aspect, for the main fraction, the enzyme to protein ratio is about 1:2000. In a further specific aspect, for the tail fraction, the enzyme to protein ratio is about 1 :500. In yet another specific aspect, for the LMW fraction, the enzyme to protein ratio is about 1 :200.

[0037] In one aspect, the liquid chromatography of step (d) comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0038] In one aspect, the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

[0039] The present disclosure provides a method for identifying HCP impurities in a sample. In some exemplary embodiments, the method comprises: (a) combining a sample comprising at least one protein of interest and at least one HCP impurity with a dissociation agent to produce a first combination; (b) subjecting the first combination to acid precipitation to produce a dissociation agent-depleted fraction; and (c) subjecting the dissociation agent-depleted fraction to liquid chromatography-mass spectrometry analysis to identify the at least one HCP impurity.

[0040] In one aspect, the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

[0041] In one aspect, the sample is incubated in the dissociation reagent for about 5 minutes to about 120 minutes, about 15 minutes, about 30 minutes, about 60 minutes, or about 120 minutes.

[0042] In one aspect, the dissociation reagent comprises at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM or about 120 mM.

[0043] In one aspect, the at least one surfactant is a detergent.

[0044] In one aspect, the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof.

[0045] In one aspect, the at least one detergent is sodium lauroyl sarcosinate, wherein the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0046] In one aspect, the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM, and the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0047] In one aspect, the at least one detergent is sodium deoxycholate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0048] In one aspect, the method further comprises subjecting the dissociation agent depleted fraction to enzymatic digestion to produce a peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (c).

[0049] In one aspect, the enzymatic digestion is a limited digestion.

[0050] In one aspect, the enzymatic digestion is performed by contacting the dissociation reagent-depleted fraction with trypsin.

[0051] In one aspect, the enzymatic digestion is performed by contacting the dissociation agent-depleted fraction with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

[0052] In one aspect, the ratio of enzyme to protein is about 1:200.

[0053] In one aspect, the method further comprises desalting the peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (c).

[0054] In one aspect, the acid precipitation is incubated for about 5 minutes to about 60 minutes, about 5 minutes, or about 60 minutes.

[0055] In one aspect, the acid precipitation comprises contacting the first combination with about 2.5% to about 10% trifluoroacetic acid, about 2.5% trifluoroacetic acid, about 5% trifluoroacetic acid, about 7.5% trifluoroacetic acid, or about 10% trifluoroacetic acid.

[0056] In one aspect, the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0057] In one aspect, the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

[0058] The present disclosure provides a method for identifying HCP impurities in a sample. In some exemplary embodiments, the method comprises: (a) combining a sample comprising at least one protein of interest and at least one HCP impurity with a dissociation agent to produce a first combination; (b) subjecting the first combination to acid precipitation to produce a dissociation agent-depleted fraction; (c) subjecting the dissociation agent-depleted fraction to buffer exchange to produce a buffer-exchanged fraction; (d) subjecting the buffer-exchanged fraction to enzymatic digestion to produce a peptide digest; and (e) subjecting the peptide digest to liquid chromatography-mass spectrometry analysis to identify the at least one HCP impurity.

[0059] In one aspect, the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

[0060] In another aspect, the dissociation reagent comprises at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM or about 120 mM.

[0061] In another aspect, the at least one surfactant is a detergent.

[0062] In yet another aspect, the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof.

[0063] In one aspect, the first combination is incubated for about 5 minutes to about 120 minutes, about 5 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes prior to the acid precipitation of step (b).

[0064] In another aspect, the at least one detergent is sodium lauroyl sarcosinate, wherein the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0065] In another aspect, the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM, and the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0066] In yet another aspect, the at least one detergent is sodium deoxycholate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

[0067] In one aspect, the enzymatic digestion is a limited digestion.

[0068] In one aspect, the enzymatic digestion is performed by contacting the buffer exchanged fraction with trypsin.

[0069] In another aspect, the enzymatic digestion is performed by contacting the buffer-exchanged fraction with a digestive enzyme at a ratio of enzyme to protein of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

[0070] In yet another aspect, the ratio of enzyme to protein is about 1:200.

[0071] In one aspect, the method further comprises desalting the peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (e).

[0072] In one aspect, the acid precipitation is incubated for about 5 minutes to about 60 minutes, about 5 minutes, or about 60 minutes.

[0073] In one aspect, the acid precipitation comprises contacting the first combination with about 2.5% to about 10% trifluoroacetic acid, about 2.5% trifluoroacetic acid, about 5% trifluoroacetic acid, about 7.5% trifluoroacetic acid, or about 10% trifluoroacetic acid.

[0074] In one aspect, the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0075] The present disclosure further provides a method for preparing a biotherapeutic product. In some exemplary embodiments, the method includes (a) subjecting a first sample comprising at least one protein of interest and at least one host cell protein (HCP) impurity to size exclusion chromatography (SEC) analysis to produce a plurality of fractions; (b) subjecting the plurality of fractions to liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis to determine the identity and amount of the at least one HCP impurity; (c) using the identity and the amount to determine whether the at least one HCP impurity is a relevant impurity of at least one of the plurality of fractions; (d) subjecting a second sample comprising the at least one protein of interest and the at least one HCP impurity to SEC analysis to produce a second plurality of fractions; and (e) using the determination of step (c), removing the at least one fraction in which the at least one HCP impurity is a relevant impurity from the plurality of fractions of step (d) to prepare a biotherapeutic product.

[0076] In one aspect, the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, a host cell protein, or a protein drug product.

[0077] In one aspect, the mobile phase for the SEC analysis comprises about 150 mM ammonium acetate.

[0078] In one aspect, the at least one HCP impurity comprises a lipase, a protease, or a combination thereof. In another aspect, the at least one HCP impurity comprises a CC motif chemokine.

[0079] In one aspect, the plurality of fractions comprises a high molecular weight (HMW) fraction, a very high molecular weight (vHMW) fraction, a dimer fraction, a monomer fraction, a low molecular weight (LMW) fraction, a tail fraction, or a combination thereof.

[0080] In one aspect, the fraction of the at least one HCP impurity that is an impurity of interest is a HMW fraction.

[0081] In one aspect, the at least one HCP impurity is present in the fraction at about 1000 parts per million (1000 ppm) to about 10000 ppm, about 1000 ppm, about 2000 ppm, about 3000 ppm, about 4000 ppm, about 5000 ppm, about 6000 ppm, about 7000 ppm, about 8000 ppm, about 9000 ppm, or about 10000 ppm.

[0082] In one aspect, the percentage of at least one HCP impurity enriched in the HMW fraction is between about 30% and about 100%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100%.

[0083] In one aspect, the method further comprises subjecting the sample of (a) to native digestion prior to SEC analysis. In a specific aspect, the native digestion is limited digestion. In another specific aspect, the native digestion is performed by contacting the sample with trypsin.

[0084] In one aspect, the LC-MS / MS analysis comprises reverse phase liquid chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, strong cation exchange chromatography, size exclusion chromatography, affinity chromatography, protein A chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0085] In one aspect, the LC-MS / MS analysis comprises parallel reaction monitoring.

[0086] The present disclosure provides an additional method for preparing a biotherapeutic product. In some exemplary embodiments, the method comprises subjecting a sample comprising a protein of interest, at least one HMW species, and at least one HCP impurity to one or more chromatography steps, wherein the one or more chromatography steps reduce the abundance of the at least one HCP impurity, wherein the at least one HCP impurity interacts with the at least one HMW species.

[0087] In one aspect, the interaction of the at least one HCP impurity with the at least one HMW species can be identified by enriching the at least one HMW species. In a specific aspect, the enrichment comprises subjecting a sample comprising the at least one HMW species and the at least one HCP impurity to SEC. In a more specific aspect, the method further comprises subjecting the at least one HMW species and the at least one HCP impurity to buffer exchange, native digestion, denaturation, molecular weight filtration, one or more additional chromatography steps and / or mass spectrometry analysis.

[0088] In one aspect, the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, a host cell protein, or a protein drug product.

[0089] In one aspect, the at least one HCP impurity comprises a lipase, a protease, or a combination thereof. In another aspect, the at least one HCP impurity comprises a CC motif chemokine.

[0090] In one aspect, the at least one HMW species comprises a dimer, an aggregate, or a combination thereof.

[0091] In one aspect, the one or more chromatography steps comprise reverse phase liquid chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, strong cation exchange chromatography, size exclusion chromatography, affinity chromatography, protein A chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

[0092] When considered in conjunction with the following description and the accompanying drawings, these and other aspects of the present invention will be better recognized and understood. Although the following description shows various embodiments and many of their specific details, it is provided in an illustrative and non-limiting manner. Many replacements, modifications, additions or rearrangements can be made within the scope of the present invention.

[0093] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. BRIEF DESCRIPTION OF THE DRAWINGS

[0094] Figure 1A Shown is the degradation of aflibercept over time at 25° C. using SDS-PAGE according to an exemplary embodiment.

[0095] Figure 1B Degradation of aflibercept over time at 37° C. using SDS-PAGE according to an exemplary embodiment is shown.

[0096] Figure 2 Shown is a SEC analysis of the aflibercept drug substance revealing cathepsin D contamination according to an exemplary embodiment.

[0097] Figure 3 Shown are SEC chromatograms of mAbl drug substance with spiked BSA in three different mobile phases according to an exemplary embodiment.

[0098] Figure 4 Shown are the number of HCPs detected in mAbl drug substance using three different mobile phases using the method of the present invention according to an exemplary embodiment.

[0099] Figure 5 Shown is a SEC chromatogram of mAbl drug substance with spiked BSA at semi-preparative scale according to an exemplary embodiment.

[0100] Figure 6Shown is a SEC chromatogram of mAbl drug substance at semi-preparative scale according to an exemplary embodiment.

[0101] Fig. 7A Shown is the amount of protein detected in each SEC fraction from mAbl drug substance according to an exemplary embodiment.

[0102] Figure 7B Shown is a UV chromatogram of each SEC fraction from the mAbl drug substance according to an exemplary embodiment.

[0103] Figure 8 Shown are the amounts of HCPs detected using various enzyme to substrate ratios in a limited digestion step according to an exemplary embodiment.

[0104] Fig. 9 Shown are the number of HCPs detected in each SEC fraction using either denaturing digestion or limited digestion according to an exemplary embodiment.

[0105] Fig.10 Shown are 10 mAU UV cutoff and 3 mAU UV cutoff in a SEC chromatogram according to an exemplary embodiment.

[0106] Fig.11 The number of HCPs detected in the mAbl drug substance using a 10 mAU UV cutoff or a 3 mAU UV cutoff using the method of the present invention according to an exemplary embodiment is shown.

[0107] Fig.12 Shown are SEC chromatograms of mAbl drug substance using 5 mg, 10 mg, or 20 mg load, according to an exemplary embodiment.

[0108] Fig.13 Shown is the number of HCPs detected in mAbl drug substance using various protein loadings using the method of the present invention according to an exemplary embodiment.

[0109] Fig.14 Shown is the number of HCPs detected in mAbl drug substance using the method of the present invention compared to previously described methods according to an exemplary embodiment.

[0110] Fig.15A The number of HCPs detected in the NISTmAb 8671 sample using the method of the present invention according to an exemplary embodiment is shown.

[0111] Fig. 15BShown is the number of HCPs detected in NISTmAb 8671 samples using the method of the present invention according to an exemplary embodiment compared to published results generated by previously described methods.

[0112] Fig.16A Shown are the number of HCPs detected in each SEC fraction in mAbl drug substance using a method of the present invention using either native mobile phase or acetonitrile (ACN) mobile phase according to an exemplary embodiment.

[0113] Fig. 16B Shown is the overlap of HCPs detected in mAbl drug substance using a method of the present invention using either a native mobile phase or an acetonitrile mobile phase according to an exemplary embodiment.

[0114] Fig.17A Shown are the masses of HCPs detected in each SEC fraction in mAbl drug substance using the method of the present invention using native mobile phase according to an exemplary embodiment.

[0115] Fig. 17B Shown are the masses of HCPs detected in each SEC fraction in mAbl drug substance using the method of the present invention using acetonitrile mobile phase according to an exemplary embodiment.

[0116] Fig.18A HCPs found to have strong binding to mAb1 detected in mAb1 drug substance using the method of the present invention according to an exemplary embodiment are shown.

[0117] Fig.18B HCPs detected in mAbl drug substance that were found not to bind to mAbl using the method of the present invention according to an exemplary embodiment are shown.

[0118] Fig. 18C HCPs found to have weak binding to mAbl detected in mAbl drug substance using the method of the present invention according to an exemplary embodiment are shown.

[0119] Fig.19 Shown is the binding profile of HCPs of particular interest in the mAbl drug substance according to an exemplary embodiment.

[0120] Fig. 20 The use of a detergent to affect the balance of bound to unbound HCPs in a biotherapeutic drug substance is demonstrated according to an exemplary embodiment.

[0121] Fig.21 Shown are SEC chromatograms of mAbl drug substance using the method of the present invention using either native mobile phase or 12mMSLS and SDC according to an exemplary embodiment.

[0122] Fig. 22 A workflow for biotherapeutic analysis including an acid precipitation step for detergent removal is shown according to an exemplary embodiment.

[0123] Fig.23 Shown are UV chromatograms of the LMW fraction of mAbl drug substance using either native mobile phase or surfactant assisted and acid precipitation process according to an exemplary embodiment.

[0124] Fig.24A Shown are the number of HCPs detected in each SEC fraction using native mobile phase, ACN mobile phase, or surfactant assisted and acid precipitation process according to an exemplary embodiment.

[0125] Fig. 24B Shown is an overlay of HCPs detected in mAbl drug substance using native mobile phase, ACN mobile phase, or surfactant assisted and acid precipitation process according to an exemplary embodiment.

[0126] Fig.25 Shown is the change of HCPs of interest in mAbl drug substance from late SEC fractions indicative of antibody bound state to early SEC fractions indicative of unbound state according to an exemplary embodiment.

[0127] Fig.26 A workflow for biotherapeutic analysis using the method of the present invention is shown according to an exemplary embodiment, the workflow comprising surfactant-assisted dissociation and acid precipitation for removal of surfactant and biotherapeutic.

[0128] Fig.27A Shown are protein spectra at 280 nm of biotherapeutic samples after incubation and acid precipitation in 6 M urea, 8 M guanidine, 5 mM acetic acid and heat, 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or 40 mM n-dodecyl-β-D-maltoside, according to an exemplary embodiment.

[0129] Fig.27B Shown is the percentage of protein retained in a biotherapeutic sample after incubation and acid precipitation in 6 M urea, 8 M guanidine, 5 mM acetic acid and heat, 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or 40 mM n-dodecyl-β-D-maltoside, according to an exemplary embodiment.

[0130] Fig.28AShown is the protein spectrum at 280 nm of a biotherapeutic sample after incubation of 500 μL of sample containing 5 mg of the biotherapeutic in 0 mM, 20 mM, 60 mM, 100 mM or 120 mM sodium deoxycholate or sodium lauroyl sarcosinate for 2 hours and incubation in 10% trifluoroacetic acid (v / v) for 30 minutes according to an exemplary embodiment.

[0131] Fig.28B Shown are total ion chromatograms of biotherapeutic samples obtained using nano-liquid chromatography-mass spectrometry after incubation of 500 μL of sample containing 5 mg of biotherapeutic in no surfactant (top panel), 60 mM sodium deoxycholate (middle panel), or 60 mM sodium lauroyl sarcosinate (bottom panel) for 2 hours and incubation in 10% trifluoroacetic acid (v / v) for 30 minutes according to an exemplary embodiment.

[0132] Fig.29A Shown are protein spectra at 280 nm of biotherapeutic samples after incubation of 500 μL of sample containing 5 mg of biotherapeutic in 20 mM, 60 mM, 100 mM or 120 mM sodium deoxycholate for 2 hours and incubation in 10% trifluoroacetic acid (v / v) for 30 minutes, according to an exemplary embodiment.

[0133] Fig.29B Shown is the percentage of protein retained in a biotherapeutic sample after incubation of 500 μL of a sample containing 5 mg of the biotherapeutic in 20 mM, 60 mM, 100 mM, or 120 mM sodium deoxycholate for 2 hours and incubation in 10% trifluoroacetic acid (v / v) for 30 minutes, according to an exemplary embodiment.

[0134] Fig. 30A Shown is the protein spectrum at 280 nm of a sample of a biotherapeutic agent after a 500 μL sample containing 5 mg of the biotherapeutic agent was incubated in 20 mM, 60 mM, 100 mM or 120 mM sodium lauroyl sarcosinate for 2 hours and incubated in 10% trifluoroacetic acid (v / v) for 30 minutes according to an exemplary embodiment.

[0135] Fig. 30B Shown is the percentage of protein retained in a biotherapeutic sample after incubation of 500 μL of a sample containing 5 mg of the biotherapeutic in 20 mM, 60 mM, 100 mM, or 120 mM sodium lauroyl sarcosinate for 2 hours and incubation in 10% trifluoroacetic acid (v / v) for 30 minutes according to an exemplary embodiment.

[0136] Fig.31A Shown are protein spectra at 280 nm of biotherapeutic samples after incubation in 20 mM sodium deoxycholate for 5 minutes, 15 minutes, 30 minutes, 60 minutes, or 120 minutes and acid precipitation, according to an exemplary embodiment.

[0137] Fig.31B Shown are protein spectra at 280 nm of biotherapeutic samples after incubation in 20 mM sodium lauroyl sarcosinate for 5 minutes, 15 minutes, 30 minutes, 60 minutes, or 120 minutes and acid precipitation, according to an exemplary embodiment.

[0138] Fig. 31C Shown is the percentage of protein retained in a biotherapeutic sample after incubation in 20 mM sodium deoxycholate or 20 mM sodium lauroyl sarcosinate for 5 minutes, 15 minutes, 30 minutes, 60 minutes, or 120 minutes and acid precipitation according to an exemplary embodiment.

[0139] Fig.32A Shown are protein spectra at 280 nm of biotherapeutic samples after incubation in 20 mM sodium deoxycholate and 0%, 2.5%, 5%, 7.5%, or 10% (v / v) of 10% trifluoroacetic acid, according to an exemplary embodiment.

[0140] Fig.32B Shown are protein spectra at 280 nm of biotherapeutic samples after incubation in 20 mM sodium lauroyl sarcosinate and 0%, 2.5%, 5%, 7.5%, or 10% (v / v) of 10% trifluoroacetic acid, according to an exemplary embodiment.

[0141] Fig.32C Shown is the percentage of protein retained in a biotherapeutic sample after incubation in 20 mM sodium deoxycholate or 20 mM sodium lauroyl sarcosinate and 0%, 2.5%, 5%, 7.5%, or 10% (v / v) of 10% trifluoroacetic acid, according to an exemplary embodiment.

[0142] Fig.33A Shown are protein spectra at 280 nm of biotherapeutic samples after 5 minutes or 60 minutes of acid precipitation according to an exemplary embodiment.

[0143] Fig.33B Total ion chromatograms of biotherapeutic samples obtained using nano-LC-MS after 5 minutes or 60 minutes of acid precipitation according to an exemplary embodiment are shown.

[0144] Fig.33C The number of HCPs identified in a biotherapeutic sample using nano-LC-MS and Protein Metrics Byonic after 5 minutes or 10 minutes of acid precipitation according to an exemplary embodiment is shown.

[0145] Fig.34AShown is the number of HCPs identified in biotherapeutic samples using nano-LC-MS and Protein Metrics, Inc., Byonic, after incubation and acid precipitation in 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or both 20 mM sodium deoxycholate and 20 mM sodium lauroyl sarcosinate, according to an exemplary embodiment.

[0146] Fig.34B A Venn diagram is shown according to an exemplary embodiment and the number of HCPs identified in biotherapeutic samples using nano-LC-MS and Protein Metrics, Inc., Byonic after incubation and acid precipitation in 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or both 20 mM sodium deoxycholate and 20 mM sodium lauroyl sarcosinate.

[0147] Fig.35A Shown is the number of HCPs identified in a sample of a biotherapeutic using nano-LC-MS and Protein Metrics, Inc., Byonic, after incubation and acid precipitation in 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or both 20 mM sodium deoxycholate and 20 mM sodium lauroyl sarcosinate or prior art methods according to an exemplary embodiment.

[0148] Fig.35B Shown is a total ion chromatogram of a sample of a biotherapeutic obtained using nano-LC-MS and ProteinMetrics, Inc. Byonic after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation or limited digestion, molecular weight cutoff filtration or ProteoMiner method according to an exemplary embodiment.

[0149] Fig.35C A Venn diagram is shown according to an exemplary embodiment and the number of HCPs identified in a sample of a biotherapeutic using nano-LC-MS and Protein Metrics, Inc., Byonic, after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation or limited digestion, molecular weight cutoff filtration, or the ProteoMiner method.

[0150] Fig.36A Shown is the distribution of isoelectric points of only HCPs identified using nano-LC-MS and ProteinMetrics, Inc. Byonic after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation or limited digestion, molecular weight cutoff filtering, and ProteoMiner method according to an exemplary embodiment.

[0151] Fig.36BShown is the distribution of hydrophilicity of only HCPs identified using nano-LC-MS and ProteinMetrics, Inc. Byonic after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation or limited digestion, molecular weight cutoff filtering and ProteoMiner method according to an exemplary embodiment.

[0152] Fig.37A Shown is the distribution of molecular weights of only HCPs identified using nano-LC-MS and ProteinMetrics, Inc. Byonic after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation or limited digestion, molecular weight cutoff filtering, and ProteoMiner method according to an exemplary embodiment.

[0153] Fig.37B Shown is the number of HCPs greater than 50 kDa (dark color) and less than 50 kDa (light color) identified only using nano-LC-MS and Protein Metrics, Byonic, after incubation in 40 mM sodium lauroyl sarcosinate and acid precipitation (outer circle) or limited digestion, molecular weight cutoff filtering and ProteoMiner method (inner circle) according to an exemplary embodiment.

[0154] Fig.38A Shown are protein spectra at 280 nm of samples of four different biotherapeutic proteins after surfactant-assisted dissociation using 40 mM sodium lauroyl sarcosinate and acid precipitation, according to an exemplary embodiment.

[0155] Fig.38B Shown is the percentage of protein retained in samples of four different biotherapeutic proteins following surfactant-assisted dissociation and acid precipitation using 40 mM sodium lauroyl sarcosinate, according to an exemplary embodiment.

[0156] Fig.39 Shown are the numbers of HCPs identified in DS and enriched HMW samples from various mAbs according to an exemplary embodiment.

[0157] Fig.40 A heat map showing HCPs identified and quantified in DS and enriched HMW samples from various mAbs according to an exemplary embodiment.

[0158] Fig.41A Shown is a comparison of the theoretical isoelectric points and molecular weights of all HCPs identified in five mAb DS samples according to an exemplary embodiment.

[0159] Fig.41BShown is a comparison of the theoretical isoelectric points and molecular weights of all HCPs identified in five mAb-enriched HMW samples according to an exemplary embodiment.

[0160] Fig.42 A heat map showing HCPs identified and quantified in enriched HMW samples, enriched dimer samples, enriched vHMW samples, and DS samples from mAb2 according to an exemplary embodiment.

[0161] Fig.43 The distribution of CC motif chemokines in the HMW fraction, monomer fraction, and LMW fraction of mAb2 according to an exemplary embodiment is shown. The inset shows a SEC chromatogram indicating the HMW fraction, monomer fraction, and LMW fraction of mAb2 according to an exemplary embodiment. DETAILED DESCRIPTION

[0162] High molecular weight (HMW) aggregates in biotherapeutic products pose challenges in drug development, commercial manufacturing, and product stability throughout the shelf life of the product. HMW aggregates may form during manufacturing, formulation, and shipment or delivery to patients. The formation of these aggregates can be attributed to various external factors, such as exposure to interfaces, freeze-thaw cycles, thermal and light stresses, and stirring stresses (Kiese et al., 2008, Journal of Pharmaceutical Sciences (J Pharm Sci)", 97(10):4347-4366; Hawe et al., 2009, European Journal of Pharmaceutical Sciences (Eur J Pharm Sci)", 38(2):79-87; Joubert et al., 2011, Journal of Biological Chemistry (J Biol Chem), 286(28):25118-25133). The presence of HMW aggregates in biotherapeutic products may affect drug efficacy and increase the risk of adverse immune responses in patients (Ratanji et al., 2014, J Immunotoxicol, 11(2):99-109). Therefore, the levels of HMW species in biotherapeutic products are monitored as critical quality attributes. In addition, various analytical methods have been developed to characterize the biophysical and biochemical properties of HMW aggregates to understand the mechanism of HMW formation and to assess the potential impact on product safety.

[0163] Recent studies have shown that the immunogenicity of HMW species is related to modifications to the primary structure. For example, oxidized species incorporated into aggregates can increase the risk of immunogenicity (Filipe et al., 2012, Monoclonal Antibodies (mAbs), 4(6): 740-752). Therefore, during the drug development process, a variety of analytical techniques are also used to study the primary structure and post-translational modifications (PTMs) of HMW species. PTMs of HMW species (such as glycosylation, glycation, deamidation, and oxidation) have been evaluated and compared with drug substances (DS).

[0164] Another potential critical quality attribute in biotherapeutic products is the presence of host cell proteins (HCPs). HCPs are process-related impurities introduced during antibody production from mammalian cell lines and must be controlled to appropriate levels to ensure product safety and efficacy. The composition and abundance of HCPs in each step of the manufacturing process and in the final drug substance depend on many factors: the host expression system (e.g., Escherichia coli (E. coli) with approximately 4,300 genes compared to Chinese hamster ovary (CHO) cells with approximately 30,000 genes), the mode of expression (e.g., cytoplasm compared to culture medium), the physicochemical properties of the biotherapeutic (e.g., hydrophobicity, charge, and structure), and the purification process (e.g., protein A chromatography, ion exchange chromatography, hydrophobic interaction chromatography, or filtration).

[0165] HCP impurities in biotherapeutic products can potentially cause many problems. HCPs can compromise patient safety: for example, HCP PLBD2 can trigger a dose-dependent immune response, and host cell cytokines such as MCP-1 or TGF-β1 can cause toxicity. They can also compromise product quality and efficacy: for example, cathepsin D can cause drug degradation, while lipases can cause degradation of polysorbates, a common excipient that helps stabilize drugs. Recent studies have shown that low levels of HCPs may lead to product fragmentation (Robert et al., 2009, Biotechnol Bioeng, 104(6):1132-1141; Dick et al., 2008, Biotechnol Bioeng, 100(6):1132-1143; Luo et al., 2019, Biotechnol Prog, 35(1):e2732), immunogenic responses (Fischer et al., 2017, Journal of the American Association of Pharmaceutical Scientists (AAPS) J) , 19(1):254-263; Jawa et al., 2016, Journal of the American Association of Pharmaceutical Scientists, 18(6):1439-1452) and formulation changes (Chiu et al., 2017, Biotechnology and Bioengineering, 114(5):1006-1015; McShan et al., 2016, PDAJ Pharm Sci Technol, 70(4):332-345; Zhang et al., 2020, Journal of Pharmaceutical Science, 109(11):3300-3307; Zhang et al., 2021, Journal of Pharmaceutical Science, 110(12):3866-3873). For example, trace amounts of lipases may degrade polysorbate 20 and polysorbate 80, causing drug product aggregation and affecting the shelf life of the product (Chiu et al.; McShan et al.; Zhang et al. 2020; Zhang et al. 2021). To guide process development, it is important to use analytical methods to evaluate key process parameters and critical quality attributes (CQAs) of biotherapeutics and biotherapeutic candidates. Therefore, highly sensitive analytical methods are needed to monitor downstream process activities and remove low concentrations of HCPs to avoid harmful clinical events. The disclosure herein provides new improvements in analytical methods for evaluating HCPs in biotherapeutic products.

[0166] Throughout the purification process, a subpopulation of residual HCPs is often co-purified with the biotherapeutic. The identification of HCPs is challenging at least in part due to the relatively high abundance of biotherapeutics, which can create technical barriers to the detection of low-abundance proteins in the sample. Various approaches have been developed to ameliorate this problem, such as using ProteoMiner beads to compress the dynamic range of protein concentrations of a sample, or using immunoassays to specifically enrich for HCPs, but each approach has coordination, technical, or analytical disadvantages.

[0167] Traditionally, enzyme-linked immunosorbent assay (ELISA) and protein blotting have been used to perform HCP analysis in biotherapeutics. However, these methods are unlikely to detect HCPs that induce weak or no immune responses. In addition, ELISA does not usually indicate the identity of individual HCPs. Because the risks posed by individual HCP species vary, methods that can provide information about individual HCPs should be implemented as an orthogonal strategy for risk mitigation (Bracewell et al., 2015, Biotechnology and Bioengineering, 112(9): 1727-1737; Abiri et al., 2018, Public Library of Science Comprehensive (PLoSONE), 13(3)e0193339).

[0168] Following recent advances in instrumentation and workflow improvements, proteomics based on liquid chromatography coupled to tandem mass spectrometry (LC-MS / MS) has become a commonly used orthogonal HCP analysis strategy. LC-MS / MS for HCP analysis not only enables the identification and quantification of individual HCPs, but also mitigates the risk of lack of coverage of specific HCPs in polyclonal antibody reagents used in ELISA HCP assays. In addition, LC-MS / MS-based HCP analysis enables understanding of downstream processes and can provide guidance for the removal of abundant or problematic HCPs.

[0169] Most monoclonal antibody (mAb) purification techniques involve an initial affinity chromatography step (e.g., Protein A affinity chromatography) followed by several polishing steps. The presence of HCPs in the Protein A eluate is primarily due to interactions with the column resin / ligand or the mAb. HCPs retained after Protein A purification due to column resin interactions may be removed in subsequent polishing steps. However, HCPs associated with mAbs are difficult to remove and may escape from the purification process. Identification of co-eluting HCPs and understanding the above interaction mechanisms are critical for process development.

[0170] The main challenge in identifying HCPs in the final drug substance (DS) by MS is the large dynamic range of concentrations. This challenge can be overcome by adding another dimension to the separation, such as 2D-LC (Yang et al., 2018, Anal Chem, 90(22): 13365-13372; Farrell et al., 2015, Anal Chem, 87(18): 9186-9193) or ion mobility (Doneanu et al., 2015, Anal Chem, 87(20): 10283-10291). Other strategies include protein A depletion (Madsen et al., 2015, Monoclonal Antibodies, 7(6): 1128-1137; Thompson et al., 2014, Rapid Commun Mass Spectrom, 28(8): 855-860; Johnson et al., 2020, Analytical Chemistry, 92(15): 10478-10484) or native digestion (Huang et al., 2017, Analytical Chemistry, 89(10): 5436-5444) to remove therapeutic proteins during sample preparation (Madsen et al.; Huang et al.). In addition, chromatographic separation can be performed before sample preparation to distinguish HCPs from therapeutic proteins. Examples of these methods include HCP analysis by reverse phase HPLC fractionation (Bomans et al., 2013, PLoS One, 8(11):e81639), strong cation exchange (SCX) fractionation (Soderquist et al., 2015, Advances in Biotechnology, 31(4):983-989), and hydrophilic interaction liquid chromatography (HILIC) fractionation (Wang et al., 2020, Analytical Chemistry, 92(15):10327-10335).

[0171] Although many characterization approaches focus on the aggregation of protein products as a causative mechanism of product problems associated with HMW species, few HCP impurities in HMW fractions have been profiled (Xu et al., 2021, Journal of Pharmaceutical Sciences, 110(10):3403-3409). Therefore, there is a need to characterize HCPs in biotherapeutic products, especially the distribution of HCPs in size-separated fractions.

[0172] The examples set forth below show several surprising discoveries, which are important for the development and manufacture of biotherapeutic products. Surprisingly, it was found that size exclusion chromatography (SEC) analytical methods can be used to identify HCPs with comparable or higher sensitivity and specificity compared to the sensitivity and specificity of alternative methods. It was further surprisingly found that the SEC analysis using a denaturing mobile phase compared to a non-denaturing mobile phase can be used to characterize the binding of HCPs to proteins of interest, and further generate the binding profiles of all detected HCPs in a sample. In addition, it was surprisingly found that the surfactant-assisted method using an acid precipitation can further enhance the detection, identification and characterization of HCPs.

[0173] Relatedly, it was surprisingly found that the HMW fraction of a biotherapeutic product can contain high abundance HCPs, and the HCPs selectively interact with specific HMW species rather than eluting based on their own size at early SEC retention times. It was also surprisingly found that samples containing unacceptably high abundance HCPs (such as total biotherapeutic product DS) can have a large percentage of these HCPs in the LMW fraction or HMW fraction. Finally, it was found that the identity and quantity of HCPs in the total drug substance and HMW fractions vary greatly in different biotherapeutic products, even when using the same purification process. These findings illustrate the potential mechanisms of harmful activity in HMW species of biotherapeutic products that can contain high abundance HCPs in a manner specific to a particular product. These findings also confirm the utility of a novel method for producing a biotherapeutic product, the utility of which includes determining whether the HMW fraction of a particular product contains a high abundance of problematic HCPs, and if so, using SEC to remove HCPs that interact with HMW species, thereby improving the quality of the product, such as stability and immunogenicity.

[0174] The present disclosure provides a method for identifying, quantifying and characterizing HCPs in a sample (e.g., a HMW fraction of a drug substance or a biotherapeutic product) and for removing the HCPs to improve the production process of a biotherapeutic product. For example, the example set forth below describes the use of native digestion to characterize HCPs in HMW enriched from a drug substance (DS). Among the five mAbs studied, the HCPs identified in the enriched HMW fractions were more than the HCPs identified in the total DS, which thus indicates that SEC can potentially be used as a fractionation strategy for enhancing HCP detection. Some commonly identified and problematic HCPs are present at higher levels in the enriched HMW fractions than in the total DS, which thus indicates that certain HCPs can preferentially interact with HMW species in biotherapeutic products. The most abundant HCPs from mAb1 (i.e., CC motif chemokines) are enriched in the HMW fractions in large quantities. Therefore, the HCP profiles of the enriched dimer fraction and the enriched very high molecular weight (vHMW) fraction were further investigated to clarify the fractions associated with the CC motif chemokine. The association of the CC motif chemokine with mAb1 was specifically attributed to the mAb1 dimer. Finally, HMW species were removed from mAb1 by SEC and MS quantification was performed to determine the CC motif chemokine levels in the HMW fraction, monomer fraction, and LMW fraction.

[0175] Unless otherwise described, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to any methods and materials described herein can be used in the practice or testing, specific methods and materials are now described.

[0176] The terms "a" and "an" should be understood to mean "at least one," and the terms "about" and "approximately" should be understood to allow for standard variations, as would be understood by one of ordinary skill in the art, and where ranges are provided, the endpoints are inclusive. As used herein, the terms "include," "includes," and "including" are intended to be non-limiting and are understood to mean "comprise," "comprises," and "comprising," respectively.

[0177] As used herein, the terms "protein" and "protein of interest" may include any amino acid polymer with covalently linked amide bonds. Proteins include one or more amino acid polymer chains, commonly referred to in the art as "polypeptides." "Polypeptides" refer to polymers consisting of amino acid residues, related naturally occurring structural variants, and synthetic non-natural analogs thereof, related naturally occurring structural variants, and synthetic non-natural analogs thereof connected by peptide bonds. "Synthetic peptides or polypeptides" refer to non-naturally occurring peptides or polypeptides. Synthetic peptides or polypeptides can be synthesized, for example, using an automated peptide synthesizer. Various solid phase peptide synthesis methods are known to those skilled in the art. Proteins may include one or more polypeptides to form a single functional biomolecule. Proteins may include antibody fragments, nanobodies, recombinant antibody chimeras, cytokines, chemokines, peptide hormones, and the like. Proteins of interest may include any of the following: biotherapeutic proteins, recombinant proteins for research or therapy, trap proteins and other chimeric receptor Fc fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, polyclonal antibodies, human antibodies, and bispecific antibodies. Proteins can be produced using recombinant cell-based production systems such as insect baculovirus systems, yeast systems (e.g., Pichia sp.), mammalian systems (e.g., CHO cells and CHO derivatives such as CHO-K1 cells). For a recent review of biotherapeutic proteins and their production, see Ghaderi et al., "Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation" (Darius Ghaderi et al., Production platforms for biotherapeutic glycoproteins - Occurrence, impact, and challenges of non-human sialylation), 28 Biotechnology and Genetic Engineering Reviews 147-176 (2012), the entire teachings of which are incorporated herein by reference). In some exemplary embodiments, the protein includes modifications, adducts, and other covalently linked moieties. These modifications, adducts and moieties include, for example, avidin, streptavidin, biotin, polysaccharides (e.g., N-acetylgalactosamine, galactose, neuraminic acid, N-acetylglucosamine, fucose, mannose and other monosaccharides), PEG, polyhistidine, FLAGtag, maltose binding protein (MBP), chitin binding protein (CBP), glutathione-S-transferase (GST) myc epitope, fluorescent labels and other dyes, etc.Proteins can be classified based on composition and solubility, and thus can include simple proteins, such as globular proteins and fibrous proteins; conjugated proteins, such as nucleoproteins, glycoproteins, mucins, chromoproteins, phosphoproteins, metalloproteins, and lipoproteins; and derived proteins, such as primary derived proteins and secondary derived proteins. Non-limiting examples of proteins or pharmaceutical protein products can include recombinant proteins, antibodies, bispecific antibodies, multispecific antibodies, antibody fragments, monoclonal antibodies, fusion proteins, scFv, and combinations thereof.

[0178] As used herein, the term "recombinant protein" refers to a protein produced by transcription and translation of a gene carried on a recombinant expression vector that has been introduced into a suitable host cell. In certain exemplary embodiments, the recombinant protein can be an antibody, for example, a chimeric antibody, a humanized antibody or a fully human antibody. In certain exemplary embodiments, the recombinant protein can be an antibody of the same type selected from the group consisting of: IgG (for example, IgG1, IgG2, IgG3, IgG4), IgM, IgA1, IgA2, IgD or IgE. In certain exemplary embodiments, the antibody molecule is a full-length antibody (for example, IgG1 or IgG4 immunoglobulin), or the antibody can be a fragment (for example, an Fc fragment or a Fab fragment).

[0179] As used herein, the term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain includes a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region includes three domains CH1, CH2, and CH3. Each light chain includes a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region includes a domain (CL1). The VH region and the VL region can be further subdivided into hypervariable regions referred to as complementary determining regions (CDRs), which are interspersed with more conservative regions referred to as framework regions (FRs). Each VH and VL is composed of three complementary determining regions and four framework regions arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In various embodiments of the present invention, the framework regions of the anti-big ET-1 antibody (or its antigen-binding portion) may be identical to human germline sequences or may be natural or artificially modified. The amino acid consensus sequence may be defined based on a side-by-side analysis of two or more complementary determining regions. As used herein, the term "antibody" also includes antigen-binding fragments of intact antibody molecules. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, etc. include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies may be derived from intact antibody molecules, for example, using any suitable standard technique (such as proteolytic digestion or recombinant genetic engineering techniques involving manipulation and expression of DNA encoding antibody variable domains and optionally constant domains). Such DNA is known and / or readily available from, for example, commercial sources, DNA libraries (including, for example, phage-antibody libraries), or may be synthesized. The DNA can be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, create cysteine ​​residues, modify, add or delete amino acids, etc.

[0180] As used herein, "antibody fragments" include a portion of a complete antibody, such as an antigen binding region or variable region of an antibody. Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, scFv fragments, Fv fragments, dsFv bifunctional antibodies, dAb fragments, Fd' fragments, Fd fragments, and isolated complementary determining regions, as well as trifunctional antibodies, tetrafunctional antibodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed by antibody fragments. Fv fragments are combinations of the variable regions of immunoglobulin heavy and light chains, and ScFv proteins are recombinant single-chain polypeptide molecules in which the immunoglobulin light and heavy chain variable regions are connected by peptide linkers. In some exemplary embodiments, an antibody fragment includes enough amino acid sequences of a parent antibody, the amino acid sequences being fragments of the parent antibody so that it binds to the same antigen as the parent antibody; in some exemplary embodiments, the fragment binds to an antigen having an affinity comparable to that of the parent antibody and / or competes with the parent antibody to bind to the antigen. Antibody fragments can be produced in any manner. For example, antibody fragments can be produced enzymatically or chemically by fragmentation of intact antibodies and / or antibody fragments can be produced recombinantly from genes encoding partial antibody sequences. Alternatively or in addition, antibody fragments can be produced synthetically in whole or in part. Antibody fragments can optionally include single-chain antibody fragments. Alternatively or in addition, antibody fragments can include multiple chains linked together, for example, by disulfide bonds. Antibody fragments can optionally include multimolecular complexes. Functional antibody fragments typically include at least about 50 amino acids, and more typically include at least about 200 amino acids.

[0181] The term "bispecific antibody" includes antibodies that can selectively bind to two or more epitopes. Bispecific antibodies generally include two different heavy chains, wherein each heavy chain specifically binds to different epitopes on two different molecules (e.g., antigens) or on the same molecule (e.g., on the same antigen). If a bispecific antibody can selectively bind to two different epitopes (a first epitope and a second epitope), the affinity of the first heavy chain to the first epitope will generally be lower than the affinity of the first heavy chain to the second epitope by at least one to two or three or four orders of magnitude, and vice versa. The epitopes recognized by the bispecific antibody can be located on the same or different targets (e.g., located on the same or different proteins). Bispecific antibodies can be prepared, for example, by combining heavy chains that recognize different epitopes of the same antigen. For example, a nucleic acid sequence encoding a heavy chain variable sequence that recognizes different epitopes of the same antigen can be fused with a nucleic acid sequence encoding different heavy chain constant regions, and such sequences can be expressed in cells expressing immunoglobulin light chains.

[0182] A typical bispecific antibody has two heavy chains, each with three heavy chain complementary determining regions, and one immunoglobulin light chain, the CDRs are followed by a CH1 domain, a hinge, a CH2 domain, and a CH3 domain, the immunoglobulin light chain does not confer antigen binding specificity but can associate with each heavy chain, or can associate with each heavy chain and can bind to one or more of the epitopes bound by the heavy chain antigen binding region, or can associate with each heavy chain and enable one or both of the heavy chains to bind to one or two epitopes. bsAbs can be divided into two major categories, those with an Fc region (IgG-like) and those lacking an Fc region, the latter being generally smaller than IgG and IgG-like bispecific molecules that include an Fc. IgG-like bispecific antibodies (bsAbs) can have different formats, such as but not limited to trifunctional antibodies, knob-into-hole IgG (KiH IgG), crossMab, orthogonal Fab IgG, dual variable domain Ig (DVD-Ig), 2-in-1 or dual-action Fab (DAF), IgG-single-chain Fv (IgG-scFv) or κλ-body. Different non-IgG-like formats include tandem scFv, diabody formats, single-chain diabodies, tandem diabodies (TandAb), dual affinity retargeting molecules (DART), DART-Fc, nanobodies or antibodies produced by the docking and locking (DNL) method (Gaowei Fan, Zujian Wang and Mingju Hao, Bispecific Antibodies and Their Applications, 8 Journal of Hematology & Oncology 130; Dafne Müller and Roland E. Kontermann, Bispecific Antibodies, Handbook of Therapeutic Antibodies 265-310 (2014), the entire teachings of which are incorporated herein). The method of producing bsAbs is not limited to the quadroma technology based on somatic cell fusion of two different hybridoma cell lines, chemical conjugation involving chemical cross-linking agents, and genetic methods using recombinant DNA technology.

[0183] As used herein, "multispecific antibodies" refer to antibodies that have binding specificities for at least two different antigens. Although these molecules will typically bind to only two antigens (i.e., bispecific antibodies, bsAbs), antibodies with additional specificities (such as trispecific antibodies and KiH trispecific antibodies) can also be addressed by the systems and methods disclosed herein.

[0184] As used herein, the term "monoclonal antibody" is not limited to antibodies produced by hybridoma technology. Monoclonal antibodies can be derived from a single clone by any means available or known in the art, including any eukaryotic clone, prokaryotic clone, or phage clone. Monoclonal antibodies useful in the present disclosure can be prepared using various techniques known in the art, including the use of hybridomas, recombinant techniques, and phage display techniques, or a combination thereof.

[0185] As used herein, the term "host cell protein" (HCP) is included in the production of recombinant proteins derived from host cells. Host cell proteins can be process-related impurities, which can be derived from the manufacturing process and can include three main categories: cell substrate-derived, cell culture-derived and downstream-derived. Cell substrate-derived impurities include, but are not limited to, proteins derived from host organisms and nucleic acids (host cell genomes, vectors or total DNA). Cell culture-derived impurities include, but are not limited to, inducers, antibiotics, serum and other medium components. Downstream derived impurities include, but are not limited to enzymes, chemical and biochemical processing reagents (e.g., cyanogen bromide, guanidine, oxidants and reductants), inorganic salts (e.g., heavy metals, arsenic, non-metallic ions), solvents, carriers, ligands (e.g., monoclonal antibodies) and other leachables. In some exemplary embodiments, the type of host cell protein in the composition can be at least two. In some exemplary embodiments, host cell proteins can be combined with biotherapeutics. In some exemplary embodiments, host cell proteins can have strong binding, weak binding or no binding with biotherapeutics. In some exemplary embodiments, the host cell protein may preferentially bind to a particular form of the biotherapeutic agent (eg, an aggregate, multimer, dimer, monomer, post-translationally modified form, truncated form, or fragment of the biotherapeutic agent).

[0186] The presence of host cell proteins in biotherapeutic products can be considered as a higher or lower risk based on many measurable factors. One such factor is the concentration or abundance (quantity) of HCP impurities in the biotherapeutic product. HCPs may not have a perceptible effect at sufficiently low abundances, as measured by, for example, ELISA or mass spectrometry. The level at which HCPs may have considerable risk may depend on the specific identity of the HCP, which level may be considered as an unacceptable level in the product and can be monitored as a critical quality attribute (CQA). Specific HCPs may be known to have a specific level of risk, such as the level of enzymatic activity of the HCP as an enzyme.

[0187] Relatedly, the criticality of the presence of an HCP may depend on the function of the HCP, particularly as it relates to a component of a biotherapeutic product. For example, an HCP lipase that may or is known to degrade polysorbates present in a biotherapeutic product of interest may be closely monitored, and a low threshold may be provided for how much HCP impurity may be allowed in a biotherapeutic product. Other particularly relevant HCPs may be, for example, proteases that may or are known to degrade a protein of interest in a biotherapeutic product, or immunogenic HCPs that may or are known to cause an immune response when administered to a subject. Using the methods of the present invention, one skilled in the art may assess the abundance, distribution, and / or identity of an HCP impurity in the context of a biotherapeutic product of interest to determine whether the HCP impurity is a relevant HCP impurity, and based on the determination, a chromatographic separation method or other separation method may be used to remove the impurity when producing the biotherapeutic product.

[0188] In some exemplary embodiments, the sample may include at least one high abundance protein or peptide and at least one HCP. In some exemplary embodiments, the concentration of at least one high abundance protein or peptide may be at least about 1000 times, 10,000 times, 100,000 times or 1,000,000 times of the concentration of at least one HCP. Another way to express relative concentration is, for example, in parts per million (ppm). It should be understood that when using ppm to describe the concentration of low abundance proteins or peptides (such as HCP) in a sample containing high abundance proteins or peptides (such as therapeutic proteins), ppm is measured relative to the concentration of high abundance proteins or peptides. In some exemplary embodiments, the concentration of at least one HCP may be less than about 1000ppm, less than about 100ppm, less than about 10ppm or less than about 1ppm.

[0189] In some exemplary embodiments, the sample may include at least one protein of interest and at least one HCP. In some exemplary embodiments, the sample may include at least one protein of interest and at least one HCP, wherein the size of the protein of interest is greater than the size of the HCP. In some exemplary embodiments, the sample may include at least one protein of interest and at least one HCP, wherein the size of the protein of interest is greater than the size of the HCP such that it can be separated using SEC. For example, a protein of interest can be greater than 50 kilodaltons (kDa), greater than 100 kDa, greater than 150 kDa, between about 50 kDa and about 250 kDa, between about 100 kDa and about 250 kDa, between about 100 kDa and about 200 kDa, between about 150 kDa and about 250 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 160 kDa, about 170 kDa, about 180 kDa, about 190 kDa, about 200 kDa, about 210 kDa, about 220 kDa, about 230 kDa, about 240 kDa, about 250 kDa, about 260 kDa, about 270 kDa, about kDa, about 280 kDa, about 290 kDa, about 300 kDa, about 310 kDa, about 320 kDa, about 330 kDa, about 340 kDa, about 350 kDa, about 360 kDa, about 370 kDa, about 380 kDa, about 390 kDa, about 400 kDa, about 410 kDa, about 420 kDa, about 430 kDa, about 440 kDa, about 450 kDa, about 460 kDa, about 470 kDa, about 480 kDa, about 490 kDa, about 500 kDa, about 510 kDa, about 520 kDa, about 530 kDa, about 540 kDa, about 550 kDa, about 560 kDa, about 570 kDa, about 580 kDa, about 590 kDa, or about 600 kDa.The host cell protein can be about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, about 5 kDa, about 6 kDa, about 7 kDa, about 8 kDa, about 9 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, about 50 kDa, about 55 kDa, about 60 kDa, about 65 kDa, about 70 kDa, about 75 kDa, about 76 kDa, about 77 kDa, about 78 kDa, about 79 kDa, about 80 kDa, about 81 kDa, about 82 kDa, about 83 kDa, about 84 kDa, about 86 kDa, about 87 kDa, about 88 kDa, about 89 kDa, about 90 kDa, about 91 kDa, about 92 kDa, about 93 kDa, about 94 kDa, about 95 kDa, about 96 kDa, about 97 kDa, about 98 kDa, about 99 kDa, about 100 kDa, about 110 kDa, about 111 kDa, about 112 kDa, about 113 kDa, about 114 kDa, about 115 kDa, about 116 kDa, about 117 kDa, about 118 kDa, about 119 kDa kDa, about 75 kDa, about 80 kDa, about 85 kDa, about 90 kDa, about 95 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 160 kDa, about 170 kDa, about 180 kDa, about 190 kDa, about 200 kDa, about 210 kDa, about 220 kDa, about 230 kDa kDa, about 240 kDa, about 250 kDa, about 260 kDa, about 270 kDa, about 280 kDa, about 290 kDa, about 300 kDa, about 310 kDa, about 320 kDa, about 330 kDa, about 340 kDa, about 350 kDa, about 360 kDa, about 370 kDa, about 380 kDa, about 390 kDa, about 400 kDa, about 410 kDa, about 4 kDa, about 40 kDa, about 430 kDa, about 440 kDa, about 450 kDa, about 460 kDa, about 470 kDa, about 480 kDa, about 490 kDa, about 500 kDa, about 510 kDa, about 520 kDa, about 530 kDa, about 540 kDa, about 550 kDa, about 560 kDa, about 570 kDa, about 580 kDa, about 590 kDa or about 600 kDa.

[0190] As used herein, a "protein drug product," "biopharmaceutical product," or "biotherapeutic agent" contains active ingredients that may be wholly or partially biological in nature. In one aspect, a protein drug product may include a peptide, protein, fusion protein, antibody, antigen, vaccine, peptide-drug conjugate, antibody-drug conjugate, protein-drug conjugate, cell, tissue, or a combination thereof. In another aspect, a protein drug product may include a recombinant, engineered, modified, mutated, or truncated version of a peptide, protein, fusion protein, antibody, antigen, vaccine, peptide-drug conjugate, antibody-drug conjugate, protein-drug conjugate, cell, tissue, or a combination thereof.

[0191] Proteins, pharmaceutical protein products, biopharmaceutical products or biotherapeutics can be produced by mammalian cells. Mammalian cells can be of human or non-human origin and can include primary epithelial cells (e.g., keratinocytes, cervical epithelial cells, bronchial epithelial cells, tracheal epithelial cells, renal epithelial cells and retinal epithelial cells), established cell lines and cell strains thereof (e.g., 293 embryonic kidney cells, BHK cells, HeLa cervical epithelial cells and PER-C6 retinal cells, MDBK (NBL-1) cells, 911 cells, CRFK cells, MDCK cells, CHO cells, BeWo cells, Chang cells, Detroit 562 cells, HeLa 229 cells, HeLa S3 cells, Hep-2 cells, KB cells, LSI80 cells, LS174T cells, NCI-H-548 cells, RPMI2650 cells, SW-13 cells, T24 cells, WI-28VA13, 2RA cells, WISH cells, BS-CI cells, LLC-MK2 cells, clone M-3 cells, 1-10 cells, RAG cells, TCMK-1 cells, Yl cells, LLC-PKi cells, PK(15) cells, GHi cells, GH3 cells, L2 cells, LLC-RC 256 cells, MHiCi cells, XC cells, MDOK cells, VSW cells and TH-1, B1 cells, BSC-1 cells, RAf cells, RK cells, PK-15 cells or their derivatives), fibroblasts from any tissue or organ (including but not limited to heart, liver, kidney, colon, intestine, esophagus, stomach, nervous tissue (brain, spinal cord), lung, vascular tissue (artery, vein, capillary), lymphoid tissue (lymph gland, adenoid, tonsil, bone marrow and blood), spleen, and fibroblasts and fibroblast-like cell lines (e.g.,CHO cells, TRG-2 cells, IMR-33 cells, Don cells, GHK-21 cells, citrullinemia cells, Dempsey cells, Detroit 551 cells, Detroit 510 cells, Detroit 525 cells, Detroit 529 cells, Detroit 532 cells, Detroit539 cells, Detroit 548 cells, Detroit 573 cells, HEL 299 cells, IMR-90 cells, MRC-5 cells, WI-38 cells, WI-26 cells, Midi cells, CHO cells, CV-1 cells, COS-1 cells, COS-3 cells, COS-7 cells, Vero cells, DBS-FrhL-2 cells, BALB / 3T3 cells, F9 cells, SV-T2 cells, M-MSV-BALB / 3T3 cells, K-BALB cells, BLO-11 cells, N OR-10 cells, C3H / IOTI / 2 cells, HSDMiC3 cells, KLN205 cells, McCoy cells, mouse L cells, cell line 2071 (mouse L) cells, LM cell line (mouse L) cells, L-MTK' (mouse L) cells, NCTC clones 2472 and 2555, SCC-PSA1 cells, Swiss / 3T3 cells, Indian muntjac cells, SIRC cells, Cn cells and Jensen cells (Jensen cells), Sp2 / 0, NS0, NS1 cells or their derivatives).

[0192] As used herein, "sample" can be obtained from any step of a bioprocess, such as cell culture fluid (CCF), harvested cell culture fluid (HCCF), any step in downstream processing, including a drug substance (DS) or drug product (DP) of a final formulated product. In some specific exemplary embodiments, the sample can be selected from any step of a downstream process of clarification, chromatography production or filtration.

[0193] In some exemplary embodiments, samples containing the protein of interest can be prepared prior to LC-MS analysis. The preparation steps can include denaturation, alkylation, dilution, digestion, precipitation, centrifugation, buffer exchange, and desalting. In some exemplary embodiments, precipitation can be mediated by acid. In some preferred exemplary embodiments, precipitation can be mediated by trifluoroacetic acid.

[0194] As used herein, the term "protein alkylating agent" or "alkylating agent" refers to an agent used to alkylate certain free amino acid residues in proteins. Non-limiting examples of protein alkylating agents are iodoacetamide (IOA / IAA), chloroacetamide (CAA), acrylamide (AA), N-ethylmaleimide (NEM), methyl methanethiosulfonate (MMTS), and 4-vinylpyridine, or a combination thereof.

[0195] As used herein, "protein denaturation" or "denaturation" may refer to the process in which the three-dimensional shape of a molecule changes from its native state. Protein denaturation may be performed using a protein denaturant. Non-limiting examples of protein denaturants include heat, high or low pH, reducing agents such as DTT, or exposure to chaotropic agents. Several chaotropic agents may be used as protein denaturants. Chaotropic solutes increase the entropy of the system by interfering with intramolecular interactions mediated by non-covalent forces such as hydrogen bonds, van der Waals forces, and hydrophobic effects. Non-limiting examples of chaotropic agents include butanol, ethanol, guanidine hydrochloride, lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, sodium dodecyl sulfate, thiourea, N-lauroylsarcosine, urea, and salts thereof. In some exemplary embodiments, a denaturant may be used in a mobile phase in a chromatographic analysis. In some exemplary embodiments, a denaturant used in a mobile phase may be acetonitrile. In some exemplary embodiments, a denaturant used in a mobile phase may be a surfactant.

[0196] As used herein, the term "digestion" refers to the hydrolysis of one or more peptide bonds of a protein. There are several methods for digesting proteins in a sample using appropriate hydrolyzing agents, such as enzymatic digestion or non-enzymatic digestion. Digestion of proteins into constituent peptides can produce a "peptide digest" that can be further analyzed using peptide mapping analysis.

[0197] As used herein, the term "digestive enzyme" refers to any of a number of different agents that can perform digestion of proteins. Non-limiting examples of hydrolytic agents that can perform enzymatic digestion include proteases from Aspergillus Saitoi, elastase, subtilisin, proteinase XIII, pepsin, trypsin, Tryp-N, chymotrypsin, Aspergillus pepsin I, LysN protease (Lys-N), LysC endoproteinase (Lys-C), endoproteinase Asp-N (Asp-N), endoproteinase Arg-C (Arg-C), endoproteinase Glu-C (Glu-C) or outer membrane protein T (OmpT), immunoglobulin degrading enzyme (IdeS) of Streptococcus pyogenes, thermolysin, papain, pronase, V8 protease or biologically activated fragments or homologs thereof or combinations thereof. For a recent review discussing available techniques for protein digestion, see Switazar et al., "Protein Digestion: An Overview of the Available Techniques and Recent Developments" (Linda Switzar, Martin Giera, and Wilfried MANiessen, PROTEIN DIGESTION: AN OVERVIEW OF THE AVAILABLE TECHNIQUES AND RECENT DEVELOPMENTS, 12 JOURNAL OF PROTEOME RESEARCH 1067-1077 (2013)).

[0198] Conventional methods use digestive enzymes under conditions and concentrations sufficient to completely digest all proteins in the sample prior to LC-MS analysis. The present disclosure has found that the identification and characterization of HCPs can be improved by limited digestion, which means that the digestive enzymes are used under conditions that do not completely digest the proteins in the sample. In some exemplary embodiments, the ratio of digestive enzyme to substrate (e.g., the ratio of enzyme to protein in the case where the enzyme is a protease and the substrate is a protein or a mixture of proteins) is selected to ensure limited digestion. In some exemplary embodiments, the ratio of digestive enzyme to substrate is less than about 1:100, less than about 1:200, less than about 1:300, less than about 1:400, less than about 1:500, less than about 1:600, less than about 1:700, less than about 1:800, less than about 1:900, less than about 1:1000, less than about 1:2000, less than about 1:3000, less than about 1:4000, less than about 1:50 00, less than about 1:6000, less than about 1:7000, less than about 1:8000, less than about 1:9000, less than about 1:10000, between about 1:100 and about 1:10000, between about 1:200 and about 1:2000, about 1:200, about 1:400, about 1:500, about 1:1000, about 1:2000, about 1:2500 or about 1:10000.

[0199] As used herein, the term "protein reducing agent" or "reducing agent" refers to an agent used to reduce disulfide bonds in proteins. Non-limiting examples of protein reducing agents used to reduce proteins are dithiothreitol (DTT), β-mercaptoethanol, Ellman's reagent, hydroxylamine hydrochloride, sodium cyanoborohydride, tris (2-carboxyethyl) phosphine hydrochloride (TCEP-HCl) or a combination thereof. Conventional methods for protein analysis (i.e., reduced peptide mapping) involve protein reduction prior to LC-MS analysis. In contrast, non-reduced peptide mapping analysis omits the reduced sample preparation step to retain endogenous disulfide bonds.

[0200] As used herein, the term "dissociation agent" refers to a class of molecules that can modulate protein-protein interactions, stabilize molecules in an unbound state, or both. In some exemplary embodiments, the dissociation agent can destabilize the interaction between at least one protein of interest and at least one HCP. In some exemplary embodiments, the dissociation agent can include a surfactant, a detergent, or both.

[0201] As used herein, the term "surfactant" refers to a class of molecules that include a hydrophobic "head" domain and a hydrophilic "tail" domain. For example, surfactants can be used to regulate the interaction of solvents with solutes, or to regulate protein-protein interactions. Surfactants can be, for example, phase transfer surfactants, ionic surfactants, anionic surfactants, cationic surfactants, or combinations thereof.

[0202] An exemplary type of surfactant that can be used in the method of the present invention is a detergent. Non-limiting examples of detergents include anionic detergents such as salts of deoxycholic acid, 1-heptanesulfonic acid, N-lauroylsarcosine, lauryl sulfate, 1-octanesulfonic acid, taurocholic acid, and sodium lauroylsarcosine (SLS); cationic detergents such as benzalkonium chloride, cetylpyridinium, methylbenzethonium chloride, and decamethonium bromide; zwitterionic detergents such as alkyl betaines, alkylamidoalkyl betaines, N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and phosphonium. Fatty acylcholine; and nonionic detergents, such as n-decyl α-D-pyranoglucoside, n-decyl β-D-pyranoglucoside, n-dodecyl β-D-maltoside, n-octyl β-D-pyranoglucoside, sorbitan esters, n-tetradecyl β-D-maltoside, triton, Nonidet-P-40, poloxamer 188 and any one of the Tween group of detergents; sodium lauryl sulfate (SLS); and sodium deoxycholate (SDC). The detergent can be a combination of multiple surfactants. With respect to protein structure, the detergent can be denatured or non-denatured. In some exemplary embodiments, the preferred detergent is a denaturing detergent. In some exemplary embodiments, the preferred detergent is SLS, SDC or a combination thereof.

[0203] As used herein, the term "liquid chromatography" refers to a process in which a biological / chemical mixture carried by a liquid may be separated into components due to the differential distribution of components when it flows through (or flows into) a stationary liquid phase or solid phase. Non-limiting examples of liquid chromatography include reversed phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, or mixed mode chromatography. In some aspects, a sample containing at least one protein or peptide digest of interest may be subjected to any one or a combination of the aforementioned chromatographic methods. The analyte separated using chromatography will be characterized by different retention times, which reflect the speed at which the analyte moves through the chromatographic column. Analytes can be compared using a chromatogram, which plots the retention time on one axis and the measured signal on the other axis, wherein the measured signal can be generated by, for example, UV detection or fluorescence detection.

[0204] Size Exclusion Chromatography (SEC) or Gel Filtration relies on the separation of components as their molecular size varies. The separation depends on the amount of time a substance spends in a porous stationary phase compared to the time in the fluid. The probability that a molecule will reside in a hole depends on the size of the molecule and the hole. In addition, the ability of a substance to penetrate into a hole is determined by the diffusion mobility of macromolecules, which is higher for small molecules. Very large macromolecules may not be able to penetrate the pores of the stationary phase at all; and, for very small macromolecules, the probability of penetration is close to one. Although components of larger molecular size move through the stationary phase faster, components of small molecular size have a longer path length through the pores of the stationary phase, and therefore retain longer in the stationary phase.

[0205] The analyte eluted from the SEC column can be separated into different fractions based on the elution time. For example, the analyte eluted earlier than the functional form (e.g., monomeric form) of the protein of interest can be roughly classified as high molecular weight (HMW) species. The HMW fraction can be further subdivided into, for example, very high molecular weight (vHMW) fractions and dimer fractions (representing the elution time of the dimer of the protein of interest). The analyte eluted later than the functional form of the protein of interest can be roughly classified as low molecular weight (LMW) species, and can be further subdivided into LMW fractions and late tail fractions.

[0206] Chromatographic material can include size exclusion material, wherein the size exclusion material is resin or film.The matrix for size exclusion is preferably an inert gel medium, and the inert gel medium can be a complex of cross-linked polysaccharides (for example, cross-linked agarose and / or dextran in the form of spherical beads).The cross-linked degree determines the size of the hole present in the swollen gel beads.Molecules greater than a certain size will not enter the gel beads, and therefore move through the chromatographic bed the fastest.The smaller molecules (such as detergents, proteins, DNA, etc.) that enter the gel beads in varying degrees according to their size and shape will be hindered when they pass through the bed.Therefore, molecules are usually eluted in the order that molecular size is reduced.

[0207] The porous chromatography resin suitable for the size exclusion chromatography of virus can be made of dextrose, agarose, polyacrylamide or silica with different physical properties.Polymer combinations can also be used.The most commonly used is the polymer combination of the trade name "SEPHADEX" that can be obtained from Amersham Biosciences.Other size exclusion supports from different structural materials are also suitable, such as Toyopearl 55F (polymethacrylate, it is from Tosoh Bioscience, Montgomery Pa., Montgomery, Pennsylvania) and Bio-Gel P-30Fine (BioRad Laboratories, Hercules, CA, Hercules, CA)).

[0208] As used herein, the term "mass spectrometer" includes a device capable of identifying specific molecular species and measuring their exact mass. The term is meant to include any molecular detector into which a polypeptide or peptide can be characterized. A mass spectrometer can include three main parts: an ion source, a mass analyzer, and a detector. The role of the ion source is to produce gas phase ions. Analyte atoms, molecules or clusters can be transferred to the gas phase and ionized in parallel (such as in the form of electrospray ionization) or by a separate process. The choice of ion source depends on the application.

[0209] In some exemplary embodiments, the mass spectrometer may be a tandem mass spectrometer. As used herein, the term "tandem mass spectrometry" encompasses techniques for obtaining structural information about sample molecules by using multiple stages of mass selection and mass separation. A prerequisite is that the sample molecules are converted to the gas phase and ionized so that fragments are formed in a predictable and controllable manner after the first mass selection step. MS / MS or MS 2 This can be done by first selecting and isolating the precursor ions (MS 1) and fragment it to obtain meaningful information to perform. Tandem MS has been successfully performed by various analyzer combinations. Which analyzer to combine for a specific application can be determined by many different factors, such as sensitivity, selectivity and speed, but also size, cost and availability. The two main categories of tandem MS methods are spatial tandem and time tandem, but there are also mixed situations, in which the time tandem analyzer is spatially or coupled to the spatial tandem analyzer. The spatial tandem mass spectrometer includes an ion source, a precursor ion activation device and at least two non-capture mass analyzers. A specific m / z separation function can be designed so that ions are selected in a section of the instrument, dissociated in the middle region, and then the product ions are transferred to another analyzer to perform m / z separation and data acquisition. In the time tandem, the mass spectrometer ions produced in the ion source can be captured, isolated, fragmented and m / z separated in the same physical device.

[0210] The peptides identified by mass spectrometry can be used as surrogate representatives of intact proteins and their post-translational modifications or other modifications. The peptides can be used for protein characterization by correlating experimental MS / MS data with theoretical MS / MS data, the latter being generated from possible peptides in a protein sequence database. The characterization includes but is not limited to sequencing the amino acids of protein fragments, determining protein sequencing, determining protein de novo sequencing, locating post-translational modifications or identifying post-translational modifications or comparability analysis or a combination thereof.

[0211] In some exemplary aspects, the mass spectrometer can work with nano-electrospray or nano-spray. As used herein, the term "nano-electrospray" or "nano-spray" refers to electrospray ionization at very low solvent flow rates (typically hundreds of nanoliters of sample solution per minute or lower) without using external solvent delivery. The electrospray infusion setting for forming nano-electrospray can use a static nano-electrospray emitter or a dynamic nano-electrospray emitter. Static nano-electrospray emitters continuously analyze small sample (analyte) solution volumes over extended time periods. Dynamic nano-electrospray emitters use capillary columns and solvent delivery systems to chromatographically separate mixtures before being analyzed by a mass spectrometer.

[0212] In some exemplary embodiments, mass spectrometry can be performed under native conditions. As used herein, the term "native conditions" can include performing mass spectrometry under conditions that retain non-covalent interactions in the analyte. For a detailed review of native MS, see the review: Elisabetta Boeri Erba and Carlo Petosa, The emerging role of native mass spectrometry in characterizing the structure and dynamics of macromolecular complexes, 24 "Protein Science" 1176-1192 (2015).

[0213] As used herein, the term "database" refers to a compilation of protein sequences that may be present in a sample (e.g., in the form of a file in FASTA format). Related protein sequences can be derived from cDNA sequences of the species being studied. Public databases that can be used to search for related protein sequences include databases hosted by, for example, Uniprot or Swiss-prot. Databases can be searched using content referred to herein as "bioinformatics tools." Bioinformatics tools provide the ability to search for unexplained MS / MS spectra for all possible sequences in the database, and provide explained (annotated) MS / MS spectra as output. Non-limiting examples of such tools are Mascot (www.matrixscience.com), Spectrum Mill (www.chem.agilent.com), PLGS (www.waters.com), PEAKS (www.bioinformaticssolutions.com), Proteinpilot (download.appliedbiosystems.com / / proteinpilot), Phenyx (www.phenyx-ms.com), Sorcerer (www.sagenresearch.com), OMSSA (www.pubchem.ncbi.nlm.nih.gov / omssa / ), X! Tandem (www.thegpm.org / TANDEM / ), Protein Prospector (prospector.ucsf.edu / prospector / mshome.htm), Byonic (www.proteinmetrics.com / products / byonic), or Sequest (fields.scripps.edu / sequest).

[0214] The present disclosure provides a method for identifying HCP impurities in a sample. In some exemplary embodiments, the method comprises: (a) subjecting a sample comprising at least one protein of interest and at least one HCP impurity to size exclusion chromatography (SEC) analysis to produce fractions; and (b) subjecting the fractions to LC-MS analysis to identify the at least one HCP impurity.

[0215] In some exemplary embodiments, the amount of protein loaded onto the SEC column can be between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg or about 20 mg.

[0216] In some exemplary embodiments, the mobile phase for SEC analysis can include acetonitrile. In some exemplary embodiments, the concentration of the acetonitrile can be between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 6% v / v, about 7% v / v, about 8% v / v, about 9% v / v, about 10% v / v, about 11% v / v, about 12% v / v, about 13% v / v, about 14% v / v, about 15% v / v, about 16% v / v, about 17% v / v, about 18% v / v, about 19% v / v or about 20% v / v.

[0217] In some exemplary embodiments, the mobile phase for SEC analysis can include at least one surfactant. In some exemplary embodiments, the concentration of the at least one surfactant can be between about 6 mM and about 36 mM, between about 10 mM and about 20 mM, between about 12 mM and about 24 mM, between about 10 mM and about 14 mM, between about 20 mM and about 28 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM, about 45 mM, about 46 mM, about 47 mM, about 48 mM, about 49 mM, about 50 mM, about 50 mM, about 51 mM, about 52 mM, about 53 mM, about 54 mM, about 55 mM, about 56 mM, about 57 mM, about 58 mM, about 59 mM, about 61 mM, about 6 about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM or about 36mM.

[0218] In some exemplary embodiments, at least one surfactant can be a detergent. In some exemplary embodiments, the sample can be incubated in a detergent. In some exemplary embodiments, the sample can be incubated in a detergent before acid precipitation. In some exemplary embodiments, the time of sample incubation in a detergent can be between about 5 minutes and about 120 minutes, between about 15 minutes and about 90 minutes, between about 30 minutes and about 75 minutes, between about 45 minutes and about 60 minutes, for about 5 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 75 minutes, about 90 minutes, about 105 minutes or about 120 minutes. In some exemplary embodiments, at least one detergent can be selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate and a combination thereof. In some exemplary embodiments, the concentration of sodium deoxycholate can be between about 6 mM and about 120 mM, between about 20 mM and about 120 mM, between about 20 mM and about 60 mM, between about 40 mM and about 60 mM, between about 6 mM and about 36 mM, between about 10 mM and about 20 mM, between about 12 mM and about 24 mM, between about 10 mM and about 14 mM, between about 20 mM and about 28 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM , about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 105mM, about 110mM, about 115mM or about 120mM.In some exemplary embodiments, the concentration of sodium lauroyl sarcosinate can be between about 6mM and about 120mM, between about 20mM and about 120mM, between about 20mM and about 60mM, between about 40mM and about 60mM, between about 6mM and about 36mM, between about 10mM and about 20mM, between about 12mM and about 24mM, between about 10mM and about 14mM, between about 20mM and about 28mM, about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM , about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM , about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 105mM, about 110mM, about 115mM or about 120mM.

[0219] In some exemplary embodiments, the method may further include subjecting the fraction to enzymatic digestion prior to LC-MS analysis. In some exemplary embodiments, the enzymatic digestion may be carried out by contacting the fraction with trypsin. In some exemplary embodiments, the enzymatic digestion may be carried out by contacting the fraction with a digestive enzyme at a ratio of about 1:100 to about 1:2000, about 1:100 to about 1:2000, about 1:50, about 1:100, about 1:150, about 1:200, about 1:300, about 1:400, about 1:500, about 1:600, about 1:700, about 1:800, about 1:900, about 1:1000 or about 1:2000 of enzyme to protein.

[0220] In some exemplary embodiments, the method may further include subjecting the fraction to acid precipitation prior to LC-MS analysis. In some exemplary embodiments, the acid precipitation may include contacting the fraction with trifluoroacetic acid. In some exemplary embodiments, the acid precipitation may include centrifugation. In some exemplary embodiments, the concentration of trifluoroacetic acid can be between about 0.5% and about 20%, between about 1% and about 10%, between about 0.5% and about 5%, between about 1% and about 2%, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%.

[0221] In some exemplary embodiments, the method may further include subjecting the fraction to buffer exchange. In some exemplary embodiments, the step of the method may be in the order of SEC analysis, acid precipitation, buffer exchange, digestion and LC-MS analysis. In some exemplary embodiments, the step of the method may be in the order of SEC analysis, buffer exchange, digestion and LC-MS analysis. In some exemplary embodiments, the step of the method may be in the order of SEC analysis, buffer exchange and LC-MS analysis. In some exemplary embodiments, the step of the method may be in the order of SEC analysis, buffer exchange and LC-MS analysis. In some exemplary embodiments, the step of the method may be in the order of acid precipitation, buffer exchange, digestion and liquid chromatography-mass spectrometry analysis. In some exemplary embodiments, the step of the method may be in the order of acid precipitation, buffer exchange, digestion, desalting and liquid chromatography-mass spectrometry analysis. In some exemplary embodiments, acid precipitation may include centrifugation.

[0222] The present disclosure also provides a method for characterizing the binding of HCP impurities to a protein of interest. In some exemplary embodiments, the method comprises: (a) obtaining a sample comprising a protein of interest and at least one HCP impurity; (b) subjecting the sample to size exclusion chromatography (SEC) analysis using a non-denaturing mobile phase to produce a native fraction; (c) subjecting the sample of (a) to SEC analysis using a denaturing mobile phase to produce a denatured fraction; (d) subjecting the native fraction and the denatured fraction to LC-MS analysis to produce a native separation profile and a denatured separation profile of the at least one HCP impurity; and (e) comparing the native separation profile with the denatured separation profile to characterize the binding of the at least one HCP impurity to the protein of interest.

[0223] In some exemplary embodiments, the amount of protein loaded onto the SEC column can be between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 0.5 mg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg or about 20 mg.

[0224] In some exemplary embodiments, the denaturing mobile phase for SEC analysis can include acetonitrile. In some exemplary embodiments, the concentration of the acetonitrile can be between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 6% v / v, about 7% v / v, about 8% v / v, about 9% v / v, about 10% v / v, about 11% v / v, about 12% v / v, about 13% v / v, about 14% v / v, about 15% v / v, about 16% v / v, about 17% v / v, about 18% v / v, about 19% v / v or about 20% v / v.

[0225] In some exemplary embodiments, a denaturing mobile phase for SEC analysis may include at least one surfactant. In some exemplary embodiments, the concentration of the at least one surfactant may be between about 6 mM and about 120 mM, between about 20 mM and about 120 mM, between about 20 mM and about 60 mM, between about 40 mM and about 60 mM, between about 6 mM and about 36 mM, between about 10 mM and about 20 mM, between about 12 mM and about 24 mM, between about 10 mM and about 14 mM, between about 20 mM and about 28 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 36 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM mM, about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM M, about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 105mM, about 110mM, about 115mM or about 120mM.

[0226] In some exemplary embodiments, at least one surfactant may be a detergent. In some exemplary embodiments, at least one detergent may be selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof. In some exemplary embodiments, the concentration of sodium deoxycholate can be between about 6 mM and about 120 mM, between about 20 mM and about 120 mM, between about 20 mM and about 60 mM, between about 40 mM and about 60 mM, between about 6 mM and about 36 mM, between about 10 mM and about 20 mM, between about 12 mM and about 24 mM, between about 10 mM and about 14 mM, between about 20 mM and about 28 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25 mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM, about 32 mM, about 33 mM, about 34 mM, about 36 mM, about 37 mM, about 38 mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM , about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 105mM, about 110mM, about 115mM or about 120mM.In some exemplary embodiments, the concentration of sodium lauroyl sarcosinate can be between about 6mM and about 120mM, between about 20mM and about 120mM, between about 20mM and about 60mM, between about 40mM and about 60mM, between about 6mM and about 36mM, between about 10mM and about 20mM, between about 12mM and about 24mM, between about 10mM and about 14mM, between about 20mM and about 28mM, about 5mM, about 6mM, about 7mM, about 8mM, about 9mM, about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM, about 20mM, about 21mM , about 22mM, about 23mM, about 24mM, about 25mM, about 26mM, about 27mM, about 28mM, about 29mM, about 30mM, about 31mM, about 32mM, about 33mM, about 34mM, about 35mM, about 36mM, about 37mM, about 38mM, about 39mM, about 40mM, about 41mM, about 42mM, about 43mM , about 44mM, about 45mM, about 46mM, about 47mM, about 48mM, about 49mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 105mM, about 110mM, about 115mM or about 120mM.

[0227] In some exemplary embodiments, the method may further include subjecting the fraction to enzymatic digestion before LC-MS analysis. In some exemplary embodiments, the enzymatic digestion may be carried out by contacting the fraction with trypsin. In some exemplary embodiments, the enzymatic digestion may be carried out by contacting the fraction with a digestive enzyme at a ratio of about 1:100 to about 1:2000, about 1:200 to about 1:2000, about 1:50, about 1:100, about 1:150, about 1:200, about 1:300, about 1:400, about 1:500, about 1:600, about 1:700, about 1:800, about 1:900, about 1:1000 or about 1:2000 of enzyme to protein.

[0228] In some exemplary embodiments, the method may further include subjecting the fraction to acid precipitation prior to LC-MS analysis. In some exemplary embodiments, the acid precipitation may include contacting the fraction with trifluoroacetic acid. In some exemplary embodiments, the concentration of trifluoroacetic acid can be between about 0.5% and about 20%, between about 1% and about 10%, between about 0.5% and about 5%, between about 1% and about 2%, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%.

[0229] In some exemplary embodiments, the method may further include subjecting the fraction to buffer exchange. In some exemplary embodiments, the method may further include desalting the peptide digest after digestion, before subjecting the peptide digest to liquid chromatography-mass spectrometry analysis, or in both cases. In some exemplary embodiments, the steps of the method may be in the order of SEC analysis, acid precipitation, buffer exchange, digestion, and LC-MS analysis. In some exemplary embodiments, the steps of the method may be in the order of SEC analysis, buffer exchange, digestion, and LC-MS analysis. In some exemplary embodiments, the steps of the method may be in the order of SEC analysis, buffer exchange, digestion, and LC-MS analysis. In some exemplary embodiments, the steps of the method may be in the order of SEC analysis, buffer exchange, and LC-MS analysis.

[0230] The present disclosure further provides a method for preparing a biotherapeutic product. In some exemplary embodiments, the method includes (a) subjecting a first sample comprising at least one protein of interest and at least one host cell protein (HCP) impurity to size exclusion chromatography (SEC) analysis to produce a plurality of fractions; (b) subjecting the plurality of fractions to liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis to determine the identity and amount of the at least one HCP impurity; (c) using the identity and the amount to determine whether the at least one HCP impurity is a relevant impurity of at least one of the plurality of fractions; (d) subjecting a second sample comprising the at least one protein of interest and the at least one HCP impurity to SEC analysis to produce a second plurality of fractions; and (e) using the determination of step (c), removing the at least one fraction in which the at least one HCP impurity is a relevant impurity from the plurality of fractions of step (d) to prepare a biotherapeutic product.

[0231] In some exemplary embodiments, the protein of interest may be an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product. In some exemplary embodiments, a sample may contain more than one protein of interest.

[0232] In some exemplary embodiments, at least one HCP impurity may include a lipase, a protease, or a combination thereof. In some exemplary embodiments, at least one HCP impurity may include a CC motif chemokine, a carboxypeptidase, a β-hexosaminidase, an α-trypsin inhibitor heavy chain H5, a lipoprotein lipase, a peptidyl-prolyl cis-trans isomerase, a cathepsin L1, an annexin, a legumain, a complement C1r-A subcomponent, a cornifin-A, a peroxidase, a sialyl O-acetylesterase, a glutathione S-transferase mu 6. G protein-coupled receptor 56, cathepsin Z, annexin, lipase, inhibitor of metalloproteinase 1, clusterin, fructose-bisphosphate aldolase, fatty acid binding protein, putative phospholipase B-like 2, acid ceramidase, cathepsin D, connective tissue growth factor, procollagen C-endopeptidase enhancing factor 1, neogenin, CD166 antigen, intercellular adhesion molecule 1, leucine-rich repeat transmembrane protein FLRT3, oncostatin M specific receptor subunit β, N-acetylglucosamine-6-sulfatase, ethanolamine-phosphate cytidylyltransferase-like protein, vasorin, tyrosine protein phosphatase non-receptor type 11, β-hexosaminidase subunit α, or a combination thereof.

[0233] In some exemplary embodiments, the plurality of fractions may include a high molecular weight (HMW) fraction, a very high molecular weight (vHMW) fraction, a multimer fraction, a dimer fraction, a monomer fraction, a low molecular weight (LMW) fraction, a tail fraction, or a combination thereof.

[0234] In some exemplary embodiments, the fraction in which the at least one HCP impurity is an impurity of interest may be a HMW fraction, a total HMW fraction, a vHMW fraction, a dimer fraction, or a LMW fraction.

[0235] In some exemplary embodiments, HCPs may be primarily enriched in the dimer fraction. In some exemplary embodiments, HCPs may be primarily enriched in the vHMW fraction.

[0236] In some exemplary embodiments, HCP may be present in an amount of about 1 ppm to about 10000 ppm, about 1 ppm, about 2 ppm, about 3 ppm, about 4 ppm, about 5 ppm, about 6 ppm, about 7 ppm, about 8 ppm, about 9 ppm, about 10 ppm, about 20 ppm, about 30 ppm, about 40 ppm, about 50 ppm, about 60 ppm, about 70 ppm, about 80 ppm, about 90 ppm, about 100 ppm, about 200 ppm, about 300 ppm, about 400 ppm, about 500 ppm, about 600 ppm, about 700 ppm, about 800 ppm, about 900 ppm, about 1000 ppm, about 1100 ppm, about 1200 ppm, about 1300 ppm, about ppm, about 1400 ppm, about 1500 ppm, about 1600 ppm, about 1700 ppm, about 1800 ppm, about 1900 ppm, about 2000 ppm, about 2100 ppm, about 2200 ppm, about 2300 ppm, about 2400 ppm, about 2500 ppm, about 3000 ppm, about 3500 ppm, about 4000 ppm, about 4500 ppm, about 5000 ppm, about 5500 ppm, about 6000 ppm, about 6500 ppm, about 7000 ppm, about 7500 ppm, about 8000 ppm, about 8500 ppm, about 9000 ppm, about 9500 ppm or about 10000 ppm is present in the fraction.

[0237] In some exemplary embodiments, the HCP is about 1 ppm to about 10000 ppm, about 1 ppm, about 2 ppm, about 3 ppm, about 4 ppm, about 5 ppm, about 6 ppm, about 7 ppm, about 8 ppm, about 9 ppm, about 10 ppm, about 20 ppm, about 30 ppm, about 40 ppm, about 50 ppm, about 60 ppm, about 70 ppm, about 80 ppm, about 90 ppm, about 100 ppm, about 200 ppm, about 300 ppm, about 400 ppm, about 500 ppm, about 600 ppm, about 700 ppm, about 800 ppm, about 900 ppm, about 1000 ppm, about 1100 ppm, about 1200 ppm, about 1300 ppm, about 1400 ppm ppm, about 1500 ppm, about 1600 ppm, about 1700 ppm, about 1800 ppm, about 1900 ppm, about 2000 ppm, about 2100 ppm, about 2200 ppm, about 2300 ppm, about 2400 ppm, about 2500 ppm, about 3000 ppm, about 3500 ppm, about 4000 ppm, about 4500 ppm, about 5000 ppm, about 5500 ppm, about 6000 ppm, about 6500 ppm, about 7000 ppm, about 7500 ppm, about 8000 ppm, about 8500 ppm, about 9000 ppm, about 9500 ppm or about 10000 ppm is present in the sample.

[0238] In some exemplary embodiments, where the HCP is a lipase, a protease, and / or an immunogenic agent, it may be identified as a relevant impurity.

[0239] In some exemplary embodiments, the percentage of HCP found in the HMW fraction can be between about 1% and about 100%, between about 20% and about 95%, between about 50% and about 90%, between about 60% and about 80%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 100%.

[0240] In some exemplary embodiments, the sample may be subjected to sample preparation prior to SEC analysis. In some exemplary embodiments, these sample preparation steps may include buffer exchange, addition of at least one internal standard at a known concentration, reduction, alkylation, filtration, deglycosylation, acidification, or a combination thereof.

[0241] In some exemplary embodiments, the sample can be subjected to sample preparation prior to LC-MS / MS analysis. In some exemplary embodiments, these sample preparation steps can include adding at least one internal standard at a known concentration, drying (e.g., using a SpeedVac), concentrating, denaturing, reducing, alkylating, digesting, acidifying, or a combination thereof.

[0242] It should be understood that the present invention is not limited to any of the aforementioned proteins, proteins of interest, antibodies, host cell proteins, protein alkylating agents, protein denaturing agents, protein reducing agents, digestive enzymes, samples, surfactants, detergents, chromatographic methods, mass spectrometers, databases, bioinformatics tools, pH, temperature or concentrations, and any protein, protein of interest, antibody, host cell protein, protein alkylating agents, protein denaturing agents, protein reducing agents, digestive enzymes, samples, surfactants, detergents, chromatographic methods, mass spectrometers, databases, bioinformatics tools, pH, temperature or concentration can be selected by any suitable means.

[0243] The present invention will be more fully understood by reference to the following examples. However, the following examples should not be construed as limiting the scope of the present invention.

[0244] Examples

[0245] Example 1: Degradation of Biotherapeutics

[0246] Aflibercept was prepared in two different manufacturing facilities and the stability of the final drug substance was evaluated using an accelerated stability study at 25 °C, as Figure 1A Degradation was indicated by the formation of non-reducing band 1 (NR-1) fragments. This study showed that the degradation of aflibercept processed in facility 2 was faster than that of aflibercept processed in facility 1. Confirmatory studies were performed by incubating aflibercept from each facility at 37°C for 2 weeks and visualizing its degradation over time using SDS-PAGE, as shown in Figure 2. Figure 1B The results of the first study were confirmed.

[0247] To investigate the cause of biotherapeutic degradation, drug substance samples from Facility 2 were subjected to size exclusion chromatography (SEC) analysis to detect any contaminating HCPs, such as Figure 2 Cathepsin D, a protease known to cause drug degradation, was detected in the aflibercept sample from Facility 2.

[0248] Example 2: Size Exclusion Chromatography Method for Host Cell Protein Identification

[0249] HCPs may end up as drug substances due to binding to biotherapeutics at some point during the purification process or throughout the purification process and / or by co-purification in an unbound form. A SEC-based HCP characterization method was developed to determine the mechanism of HCP contamination in a sample, which was designed as an orthogonal separation method for size-based enrichment of HCPs. SEC has not been previously reported as an analytical method for HCP identification in process development.

[0250] An analytical scale separation of analytes from an exemplary therapeutic protein sample mAb1 was performed as follows. The concentration of mAb was 25 mg / mL. An exemplary chromatography system suitable for this method is a Waters Xbridge Protein HPLC System with a fraction collector. Waters Acquity UPLC with SEC (7.8 x 300 mm, 3.5 μm) column. 500 μg of sample was injected in 2 replicates. The spiked standards used included BSA (66.5 kDa) and angiotensin (1 kDa). The mobile phases tested included native (non-denaturing) mobile phase, denaturing mobile phase with 2 M urea, and denaturing mobile phase with 20% acetonitrile.

[0251] SEC analysis of mAb1 was performed using BSA as a standard using the three described mobile phases, as follows: Figure 3 Based on these results, three different fractions were identified and collected for further analysis: a high molecular weight (HMW) fraction, a main fraction containing the mAb peak, and a low molecular weight (LMW) fraction. The collected SEC fractions were further subjected to LC-MS analysis and the number of HCPs identified in each fraction and using each mobile phase was compared, as shown in FIG. Figure 4 In all cases, the majority of HCPs were enriched in the LMW fraction. Based on the total number of HCPs detected, denaturation conditions using 20% ​​acetonitrile were selected for further optimization.

[0252] Example 3: Optimization of a size exclusion chromatography method for host cell protein identification

[0253] Based on the results of the analytical scale SEC method described above, the amount of protein loaded was increased to create a semi-preparative scale SEC method. An exemplary chromatography system suitable for this method is an AKTA Pure 25 chromatography system with a Cytiva Superdex 200 Increase 10 / 300 GL (8.6 μm) column. The feasibility of the semi-preparative scale method was tested using spiked BSA as a standard, as shown in FIG. Figure 5 As shown. Based on the method optimization, the final semi-preparative SEC parameters included loading 5 mg of protein (e.g., mAb1), using a denaturing mobile phase including 20% ​​acetonitrile, a flow rate of 0.5 mL / min, and collecting at 0.25 mL / well. The fractions of interest from the SEC chromatogram were defined as the HMW fraction from 0.3 column volumes (CV) to the front of 5 milli-absorbance units (mAU), the main fraction from the front of 5 mAU to the end of 40 mAU, the tail fraction from the front of 40 mAU to the end of 10 mAU, and the LMW fraction from the front of 10 mAU to 1.1 CV, as shown. Figure 6 shown.

[0254] Estimate the amount of protein in each fraction using reinjection, as Fig. 7A and Figure 7B As shown. Each collected fraction was injected into SEC again to check the purity of the collected fractions. About 95% of the mAb was enriched in the main fraction. During the buffer exchange, about 5% of the sample was lost. HCP is expected to be enriched in the HMW fraction, tail fraction and LMW fraction.

[0255] The method was further optimized using limited digestion, which has previously been shown to be useful for HCP analysis. In order to produce limited digestion, the ratio of enzyme to protein (substrate) must be optimized. Testing of limited digestion using a range of enzyme to protein ratios is shown in Figure 8 The optimized enzyme to protein ratios selected were: 1:200 for the HMW fraction, 1:2000 for the main fraction, 1:500 for the tail fraction, and 1:200 for the LMW fraction. The optimized limited digestion step was compared with the denaturing digestion step in conjunction with the SEC method of the present invention and was found to show an improved ability to identify HCPs, such as Fig. 9 shown.

[0256] Additional optimization of the methods of the invention involved testing the definition of the tail fraction and the LMW fraction at different UV mAU values, which would affect the depletion of the antibody drug product from the fractions tested and the sensitivity of HCP detection. A 10 mAU cutoff and a 3 mAU cutoff were evaluated, as Fig.10The number of HCPs identified using each cutoff value was compared as shown in Fig.11 A cut-off value of 3 mAU was found to be more effective and was selected for use in the optimized method of the present invention.

[0257] The loading amount for the semi-preparative scale method was further optimized by testing increasing amounts of protein. SEC chromatograms for the method using 5 mg protein (small blue peak), 10 mg protein (medium green peak), or 20 mg protein (large black peak) are shown in Fig.12 The number of HCPs identified using a loading of 1 mg, 5 mg, 10 mg, or 20 mg was compared, as shown in Figure 2. Fig.13 As shown. A positive correlation was found between the amount loaded and the number of HCPs detected, but the highest loading of 20 mg distorted the peak shape due to overloading. Therefore, 10 mg was selected as the optimized loading amount. By loading 10 mg per run, a higher total loading amount can be achieved.

[0258] The ability of the methods of the present invention to detect HCPs was compared with previously described methods. mAbl samples were subjected to HCP analysis using immunoprecipitation, limited digestion, molecular weight cutoff filtration, ProteoMiner beads, ProteoMiner with limited digestion, or the SEC limited digestion method of the present invention, such as Fig.14 The method of the present invention was found to be more effective than almost any previously described method.

[0259] Additional comparisons were performed using the protein standard NISTmAb 8671. A total of 544 HCPs were identified in the NISTmAb sample using the method of the present invention, such as Fig.15A This result was compared with historical data from NISTmAb analysis using a previously described method and was found to be quite robust, as shown in Figure 2. Fig. 15B shown.

[0260] Example 4: Size Exclusion Chromatography Method for Host Cell Protein Binding Analysis

[0261] An advantage of the method of the present invention is that due to the separation mechanism of SEC, HCPs can be analyzed based on size. In addition to obtaining information about the size of the protein itself, this also provides information about the binding characteristics of the protein because a protein bound to another protein will show a significant change in size. This distinction can be evaluated using a comparison between proteins separated using a native mobile phase, which will preserve protein-protein interactions, and the same proteins separated using a mildly denaturing mobile phase (such as 20% acetonitrile), which will eliminate weak protein-protein interactions without destroying strong protein-protein interactions.

[0262] The sensitivity of the method of the present invention performed with two different mobile phases was evaluated using the UPS2 standard. UPS2 is a commercially available proteomics standard that includes 48 human proteins across a wide concentration dynamic range of many orders of magnitude. Using the optimized conditions described above, mAbl was fractionated with one of two different mobile phases: native mobile phase, non-denaturing mobile phase, or a denaturing mobile phase including 20% ​​acetonitrile. The number of UPS2 proteins detected at each concentration level under each condition is shown in Table 1. Ppm is given as a molar ratio.

[0263] Table 1: UPS2 detected using native mobile phase or 20% acetonitrile mobile phase

[0264]

[0265] The amount of HCP in each fraction from the mAbl sample detected by the method of the present invention using either native mobile phase or 20% acetonitrile mobile phase was compared, as shown in FIG. Fig.16A More HCPs were detected in the HMW fraction and main fraction using native mobile phase, while more HCPs were detected in the tail fraction and LMW fraction using 20% ​​acetonitrile mobile phase. The overlap of total HCPs detected under each condition is shown in Fig. 16B middle.

[0266] The HCPs identified under each condition were further characterized by molecular weight, e.g. Fig.17A and Fig. 17B As shown. Overall, the molecular weight decreases from the HMW fraction to the LMW fraction, which is consistent with the separation mechanism of SEC. However, the HMW fraction also contains proteins with molecular weights lower than what would be expected (e.g., less than 100 kDa), indicating that their retention time in the SEC column is shorter due to binding to mAb1.

[0267] To generate a binding profile for all detected HCPs, the apparent size of each HCP identified by SEC under either native (non-denaturing) or denaturing conditions was compared as shown in Table 2.

[0268] Table 2: Host cell protein separation by size exclusion chromatography under native or denaturing conditions

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275] Comparison of the SEC separation of each HCP under each condition can be used to infer the binding properties of each HCP to the biotherapeutic. For example, it can be inferred that the HCP found in the HMW fraction under both native and denatured conditions has a relatively strong binding to mAb1 that cannot be dissociated by mild denaturation with 20% acetonitrile, as shown in Figure 2. Fig.18A It can be inferred that the HCPs found in the LMW fractions under both conditions did not bind effectively to mAb1, as shown in Fig.18B It can be inferred that the HCPs found in the HMW fraction under native conditions but shifted to the early fractions under denaturing conditions had relatively weak binding to mAb1, which was disrupted by 20% acetonitrile, as shown in Fig. 18C As shown. It can be inferred that HCPs found in the mixture of HMW and other fractions under both conditions may have relatively weak binding to mAb1, which is not affected by 20% acetonitrile. Finally, it can be inferred that HCPs found mainly in the HMW fraction under denaturing conditions but not under native conditions have binding that is re-equilibrated by acetonitrile.

[0276] Using this analysis, a binding profile for HCPs of particular interest for a given biotherapeutic can be generated. Fig.19 Binding profiles of HCPs of particular interest in the mAbl drug substance are shown. For example, cathepsin D was found to bind to mAbl during purification, but this interaction was weak and could be disrupted using 20% ​​acetonitrile. This HCP binding profiling analysis can be used to inform process development of any biotherapeutic.

[0277] Example 5: Surfactant-Assisted Size Exclusion Chromatography Method for Host Cell Protein Analysis

[0278] Inspired by the above HCP binding profiling, a surfactant-assisted dissociation method was developed to enrich HCPs from biotherapeutic samples.

[0279] HCP can exist in equilibrium between the biotherapeutic agent-bound state and the biotherapeutic agent-unbound state, such as Fig. 20To disrupt this equilibrium bound state and stabilize the unbound state, thereby preventing co-purification of HCPs with the biotherapeutic, various detergents were tested as part of the biotherapeutic production process. SEC separation profiles for mAb1 samples were generated using either native mobile phase or a mobile phase that included 12 mM sodium lauroyl sarcosinate (SLS) and 12 mM sodium deoxycholate (SDC). Fig.21 A shift in retention time was observed, which indicates partial denaturation of the antibody and / or the formation of micelles / liposomes.

[0280] High levels of surfactants may adversely affect digestion and MS analysis. Surfactants were found to be difficult to remove during buffer exchange. To address the problem of effective removal of surfactants prior to digestion and MS analysis, an optimized sample preparation method was developed, such as Fig. 22 An acid precipitation step with about 1% trifluoroacetic acid (TFA) was used to remove the surfactant, followed by a buffer exchange step, which successfully removed SLS and SDC; this is referred to as the "surfactant-assisted" or "surfactant-assisted" SEC method of the present invention.

[0281] The effect of acid precipitation on HCP enrichment and analysis was further evaluated. Acid precipitation resulted in partial removal of mAb1, e.g. Fig.23 The ability of the optimized surfactant-assisted method using SLS and SDC and acid precipitation to detect HCPs in mAb1 samples was compared to the ability of the method using native mobile phase or ACN mobile phase, as shown in Fig.24A and Fig. 24B A higher number of HCPs were detected using the surfactant-assisted method compared to the native mobile phase or ACN mobile phase.

[0282] The sensitivity of the method was tested using UPS2 standards, and the surfactant-assisted method (SLS+SDC) was shown to be more sensitive than the method using native mobile phase or ACN mobile phase, as shown in Table 3. Without being bound by theory, the acid precipitation step may preferentially precipitate mAb1 over HCPs due to the larger size of mAb1, thereby further enriching HCPs in the sample. This effect would be expected for any large protein of interest (e.g., an antibody or antibody fusion protein).

[0283] Table 3: UPS2 detected using native mobile phase, acetonitrile mobile phase or surfactant-assisted method

[0284]

[0285] The surfactant-assisted approach resulted in the translocation of the HCP of interest from the HMW fraction to the LMW fraction, demonstrating that the binding of the HCP to the biotherapeutic was successfully disrupted and that HCP enrichment and analysis were improved, as shown in Figure 2. Fig.25 shown.

[0286] Example 6: Optimization of the surfactant-assisted acid precipitation method for host cell protein analysis

[0287] Fig.26 The workflow of a surfactant-assisted acid precipitation method for enriching and identifying HCPs in biotherapeutic samples is shown. In the acid precipitation step, the biotherapeutic sample is incubated in a surfactant, then incubated in acid, and centrifuged to remove the surfactant and biotherapeutic. Ultraviolet absorption at 280 nm (UV A280) is used to determine the protein concentration of the sample after acid precipitation, which is used as an indicator of the efficacy of the acid precipitation parameters. Subsequently, the sample buffer is exchanged, and the biotherapeutic sample is digested, desalted, and analyzed using nano-liquid chromatography-mass spectrometry and ProteinMetrics, Byonic. The clarity of the spectrum and host cell protein identification in the total ion chromatogram are also used as indicators of the efficacy of the acid precipitation parameters.

[0288] The effects of various dissociation reagents on proteins in biotherapeutic samples subjected to acid precipitation were evaluated. The surfactants sodium deoxycholate, sodium lauroyl sarcosinate, and n-dodecyl-β-D-maltoside can be used as dissociation reagents. Fig.27A and Fig.27B Acid precipitation was shown to deplete 99.92%, 99.98% and 11.38% of the proteins in biotherapeutic samples incubated in 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate and 40 mM n-dodecyl-β-D-maltoside, respectively. Additionally, 6 M urea, 8 M guanidine and 5 mM acetic acid with heat can be used as dissociation agents. Fig.27A and Fig.27B Acid precipitation was shown to deplete 16.6%, 10.02% and 15.58% of the protein in biotherapeutic samples incubated in 6M urea, 8M guanidine and 5mM acetic acid with heat, respectively. These data indicate that sodium deoxycholate and sodium lauroyl sarcosinate are unique surfactants that can be used in conjunction with acid precipitation to deplete protein in biotherapeutic samples.

[0289] The effect of sodium deoxycholate and sodium lauroyl sarcosinate concentration on protein depletion in biotherapeutic samples subjected to acid precipitation was examined. Each biotherapeutic sample was 500 μL, containing 5 mg of biotherapeutic agent, and was incubated for 2 hours in 0 mM, 20 mM, 60 mM, 100 mM, or 120 mM sodium deoxycholate or sodium lauroyl sarcosinate and incubated for 30 minutes in 10% acid (v / v). Figure 28 shows that acid precipitation depleted protein more effectively in biotherapeutic samples incubated in sodium deoxycholate or sodium lauroyl sarcosinate. Figures 29 and 30 show that incubating the biotherapeutic sample in 10% acid (v / v) for 30 minutes can deplete 99.5% of the protein in the biotherapeutic sample after incubation for 2 hours in 40 mM sodium deoxycholate and 40 mM sodium lauroyl sarcosinate, respectively.

[0290] The effect of sodium deoxycholate and sodium lauroyl sarcosinate incubation time on protein depletion in biotherapeutic samples subjected to acid precipitation was determined. Prior to acid precipitation, each biotherapeutic sample was incubated in 20 mM sodium deoxycholate or 20 mM sodium lauroyl sarcosinate for 5 minutes, 15 minutes, 30 minutes, 60 minutes, or 120 minutes. Figure 31 shows that the longer the sample was incubated in 20 mM sodium deoxycholate or 20 mM sodium lauroyl sarcosinate, the more effectively the acid precipitation depleted the protein in the biotherapeutic sample, especially for incubation times up to about 60 minutes, which resulted in over 99.5% depletion of the protein.

[0291] The effect of acid precipitation pH on protein depletion in biotherapeutic samples was studied. Each biotherapeutic sample was incubated in 20 mM sodium deoxycholate or 20 mM sodium lauroyl sarcosinate and 0%, 2.5%, 5%, 7.5% or 10% (v / v) of 10% trifluoroacetic acid. Figure 32 shows that proteins depleted using higher percentages (v / v) of 10% trifluoroacetic acid more effectively lowered the acid precipitation pH, especially for percentages (v / v) of 10% trifluoroacetic acid up to about 7.5%, and precipitation using more than 7.5% (v / v) of 10% trifluoroacetic acid depleted more than 99.5% of the protein.

[0292] The effect of acid incubation time on protein depletion in biotherapeutic protein samples was evaluated. Each biotherapeutic sample was incubated in acid for either 5 minutes or 60 minutes. Fig.33A and Fig.33B showed that incubating the biotherapeutic samples in acid for more than 5 minutes did not more effectively deplete the samples of protein. Fig.33C It was shown that incubating the biotherapeutic samples in acid for more than 5 minutes did not enable the identification of additional HCPs.

[0293] The effect of incubating biotherapeutic samples in sodium deoxycholate and sodium lauroyl sarcosinate on HCP identification using a surfactant-assisted acid precipitation method was determined. Each biotherapeutic sample was incubated in 40 mM sodium deoxycholate, 40 mM sodium lauroyl sarcosinate, or both 20 mM sodium deoxycholate and 20 mM sodium lauroyl sarcosinate and subjected to acid precipitation prior to HCP identification using nano-liquid chromatography-mass spectrometry and Protein Metrics, Inc. Byonic. Figure 34 shows that the surfactant-assisted acid precipitation method identified 109, 103, and 43 HCPs in biotherapeutic samples incubated in 40 mM sodium lauroyl sarcosinate, 20 mM sodium deoxycholate and both 20 mM sodium deoxycholate, and 40 mM sodium deoxycholate, respectively. These data indicate that incubation of the biotherapeutic sample in sodium lauroyl sarcosinate enabled the identification of the most HCPs using a surfactant-assisted acid precipitation method, followed by incubation of the biotherapeutic sample in both sodium deoxycholate and sodium lauroyl sarcosinate and in sodium deoxycholate, respectively. In contrast, Figure 35 shows that ProteoMiner and limited digestion, ProteoMiner, molecular weight cutoff filtration, limited digestion, and immunoprecipitation methods identified 199, 113, 63, 53, and 32 HCPs, respectively, in the same sample of biotherapeutic, 104 of which were not identified using a surfactant-assisted acid precipitation method after incubation in 40 mM sodium lauroyl sarcosinate. These data indicate that HCPs identified using a surfactant-assisted acid precipitation method after incubation in sodium lauroyl sarcosinate may have unique properties that hinder detection using other methods.

[0294] The HCP identified by the surfactant-assisted acid precipitation method after incubation in 40mM sodium lauroyl sarcosinate is characterized. Figure 36 shows that the HCP identified by the surfactant-assisted acid precipitation method after incubation in 40mM sodium lauroyl sarcosinate is generally more acidic and more hydrophilic than the HCP identified by limited digestion, molecular weight cutoff filtration and ProteoMiner method. In addition, Figure 37 shows that the HCP identified by the surfactant-assisted acid precipitation method after incubation in 40mM sodium lauroyl sarcosinate is generally larger (e.g., greater than 50kDa) than the host cell protein identified by limited digestion, molecular weight cutoff filtration and ProteoMiner method. These data show that the characteristics of the HCP identified by the surfactant-assisted acid precipitation method after incubation in 40mM sodium lauroyl sarcosinate may affect the detection or depletion thereof using other HCP identification methods. For example, Figure 38 shows that incubation of samples of four different biotherapeutics in 40 mM sodium lauroyl sarcosinate and acid precipitation resulted in 92.22%, 99.3%, 99.92%, and 99.98% depletion of protein. These data suggest that the efficacy of protein depletion in biotherapeutic samples using 40 mM sodium lauroyl sarcosinate and acid precipitation depends on the physicochemical properties of the biotherapeutic and that the efficacy of protein depletion may affect the detection of HCPs.

[0295] Example 7: HCP profiling in the enriched HMW fraction

[0296] To further characterize HCP contaminants in recombinant protein samples (eg, monoclonal antibody drug substances), novel methods for identifying, characterizing, and removing HCPs from enriched HMW fractions of drug substances were developed. This example illustrates the workflow of an exemplary method taught in subsequent examples.

[0297] Materials. Monoclonal antibody DS and enriched HMW were generated in-house. 10KDa filters were purchased from Pall (New York, NY), and 3K Amicon ultracentrifugal filters were obtained from MilliporeSigma (Burlington, MA). Dithiothreitol (DTT) and iodoacetamide (IAM) were purchased from Thermo Scientific (Rockford, IL). Sequencing-grade modified trypsin was obtained from Promega (Madison, WI). Tris-HCl buffer (pH 7.5) was purchased from Invitrogen (Carlsbad, CA). Urea and acetic acid were purchased from Sigma-Aldrich (St. Louis, MO). PNGase F was purchased from New England Biolabs (Ipswich, MA). LC-MS grade 0.1% formic acid in water and 0.1% formic acid in acetonitrile were from Honeywell (Charlotte, NC).

[0298] Tryptic digestion of DS and enriched HMW species. Enriched HMW species were generated internally by preparative SEC of DS. HCP analysis was performed on mAb and enriched HMW fractions using a native digestion method similar to a previously disclosed method (Huang et al.), which used an optimized enzyme-to-substance ratio and a spiked recombinant protein internal standard. In short, all sample buffers were exchanged into water using a 3KDa centrifugal filter. After buffer exchange, the concentration of each sample was measured by nanodrop. Subsequently, 2 mg of each sample was spiked with two internal protein standards of known concentration (i.e., recombinant human IL33 and heavy isotope-labeled CHO putative phospholipase B-like 2 (PLBD2)). The samples were then digested overnight at 37 ° C with trypsin (1: 1000 w / w enzyme: substrate ratio). After digestion, the disulfide bonds were reduced by adding 2 μL 25 mg / mL of DTT and incubated at 90 ° C for 20 minutes. The reduced sample was further alkylated by adding 2 μL 0.25 M IAM for 30 minutes at room temperature in the dark. The final digest was filtered using a 10 KDa MW molecular weight cutoff filter. The flow through was acidified with 5 μL 10% formic acid and collected for analysis.

[0299] Fraction collection. Enriched dimer, monomer, and low molecular weight fractions were prepared from DS by SEC. PNGase F was added to 100 μg DS sample for deglycosylation (1:5 w / w enzyme to protein ratio) for 1 hour. Proteins were separated and collected on a Waters ACQUITY UPLC system (1.7 μm, 4.6 mm×300 mm) operated at an isocratic flow rate of 0.2 ml / min with a mobile phase of 150 mM ammonium acetate. The UV detector was set to a wavelength of 280 nm.

[0300] Trypsin digestion of fractionated samples. Each collected fraction was spiked with 0.01 μg of heavy isotope labeled PLBD2 as an internal standard. All samples were dried with a SpeedVac instrument and then recovered in 20 μL denaturation buffer consisting of 0.1M Tris-HCl (pH 7.5), 8M urea and 10mM DTT. The samples were denatured and reduced at 56°C for 30 minutes and then alkylated with 50mM IAM at room temperature in the dark for 30 minutes. Subsequently, the samples were digested with 100 μL of 20 ng / μL of trypsin and incubated overnight at 37°C. The digestion was quenched by adding 5 μL of acetic acid.

[0301] LC-MS / MS Analysis. The digested samples were analyzed using a Waters ACQUITY UPLC system coupled to a Thermo Scientific Q Exactive Plus mass spectrometer. The UPLC system was equipped with a Waters CSH C18 column (1.7 μm particle size, 2.1 mm×150 mm). Mobile phase A was 0.1% formic acid in water, and mobile phase B was acetonitrile containing 0.1% formic acid. The flow rate was 0.25 ml / min, and the linear LC gradient was set as follows: 0.1% B at 0-5 minutes, 32% B at 85 minutes, 40% B at 90 minutes, 90% B at 95-105 minutes, and 0.1% B at 106-125 minutes. Mass spectrometry data acquisition was performed using the top ten DDA method. The MS1 scan range was 300-1500 m / z at 70k resolution (m / z 400). The MS / MS isolation window was set to 3 m / z and the normal collision energy (NCE) was set to 28. The minimum automatic gain control (AGC) was set to 5e4 with a maximum IT of 300 msec.

[0302] The directly digested samples were analyzed using an UltiMate 3000RSLCnano system (Thermo Scientific) coupled to a Q-Exactive HFX mass spectrometer (Thermo Scientific). The RSLCnano system was equipped with an Acclaim PepMap100 75 μm×2 cm trapping column and an Acclaim PepMap 75 μm×25 cm C18 analytical column. Mobile phase A was 0.1% formic acid in water, and mobile phase B was 80% acetonitrile solution containing 0.1% formic acid. The flow rate was 300 nanoliters / minute, and the linear LC gradient was set as follows: 3% B at 0-5 minutes, 25% B at 40 minutes, 37% B at 48 minutes, 95% B at 53-58 minutes, and 3% B at 58-60 minutes. Each sample was analyzed using full mass scanning following parallel reaction monitoring (PRM) mode. A full mass scan was set up at 120k resolution with an AGC target of 1e6, a max IT of 60 ms, and a scan range of 350-2000 m / z. The PRM was set up with an isolation window of 3 m / z, a resolution of 30K, NCE set to 27, AGC of 2e5, and a max IT of 150 ms.

[0303] Data analysis. Raw files were searched against the Uniprot Cricetulus griseus proteome database using SEQUEST and Mascot (Matrix Science) by Proteome Discoverer 2.2 (Thermo Scientific). Precursor mass tolerance was set to 10ppm, and fragment ion mass tolerance was set to 0.02Da. Trypsin was set to digestive enzyme. Methionine oxidation was set to dynamic modification, and cysteine ​​alkylation was set to static modification. Proteins with high quality MS / MS spectra with at least two unique peptides and peptide lengths>6 amino acids were filtered as true positives. Skyline was used for peak integration and additional analysis.

[0304] For native digest samples, heavy isotope labeled PLBD2 was used as a qualitative control to verify digestion efficacy and HCP signal intensity. The relative abundance of each identified protein was averaged by dividing the peak area of ​​the top two to three peptides of each host cell protein by the average abundance of the top three peptides of recombinant human IL33 for quantification, where the internal standard was spiked at 50 ppm (micromolar standard to molar number of antibody). All results are calculated as molar ratio ppm.

[0305] For samples analyzed by PRM, the relative abundance of each protein was quantified by averaging the product ion area of ​​the peptides of each host cell protein divided by the average abundance of the top three peptides of heavy isotope-labeled PLBD2, where the internal standard was spiked at 0.01 μg for each sample. Results were calculated in fmol.

[0306] Experimental Design. HCP analysis was performed on five in-house produced mAbs and their enriched HMW species. DS and enriched HMW species were subjected to buffer exchange and concentrations were determined prior to sample analysis. Sample preparation was performed using the optimized native digestion method introduced by Huang in 2017. The native digestion method has been adopted by many HCP workflows in the industry due to its simplicity and effectiveness in reducing the dynamic range of the analyte. Briefly, a small amount of trypsin is added to the sample without a denaturation step. Antibodies are minimally digested under native conditions, while HCPs are preferentially digested. After digestion, the sample is denatured in a heating step and undigested antibodies are removed by precipitation. HCP peptides are injected into the LC-MS / MS instrument for analysis with minimal matrix interference. The levels of HCPs are calculated in molar ratio ppm (micromoles of HCP to moles of antibody) using the ratio of the top three most abundant peptides from HCPs to the spiked standards. The reporting of the molar ratio between HCPs and antibodies enables fair comparisons by considering the broad molecular weight distribution of HCPs present in the samples.

[0307] Example 8: HCP profiling of DS and enriched HMW species from five mAbs

[0308] The number of HCPs (>0.1 ppm) identified in all samples using the workflow described in Example 7 is shown in Fig.39 In. For each mAb, the blue bar on the left represents the number of HCPs identified from DS, and the red bar on the right represents the number of HCPs identified from the enriched HMW. For all five mAbs, the HCPs detected from the enriched HMW are more than the HCPs detected from the DS. A total of 110, 110, 105, 100 and 101 HCPs were identified in the enriched HMW fractions from mAb2 to mAb6, respectively. In contrast, only 26, 68, 76, 64 and 58 HCPs were identified from mAb2 to mAb6 DS. The total identified HCPs from HMW vary from sample to sample, which shows the molecular dependence of the HCP enrichment in HMW. It is worth noting that for mAb2, the number of HCPs identified in the enriched HMW is four times that of the HCPs identified in DS.

[0309] Twenty-five frequently identified HCPs and their estimated amounts in ppm molar ratio are listed in Fig.40 The HCPs are listed in order of abundance of the HMW species of mAb 2. The heat map is colored by HCP abundance, which ranges from 0 ppm (blue, not detected) to over 100 ppm (red).

[0310] For all five mAbs, most of the commonly identified HCPs are preferentially enriched in HMW. For example, CC motif chemokines are dominant HCPs, 37.4ppm in mAb2, and are identified in all five mAbs, with higher abundance in enriched HMW than in DS. The HMW of mAb2 shows that the CC motif chemokine level (1738.5ppm) is significantly higher than the CC motif chemokine level (20.9-61.6ppm) in other mAb HMW fractions. Metalloproteinase inhibitor 1 (TIMP1) (i.e., HCPs frequently identified from different processing steps) (Singh et al., 2020, "Biotechnology Progress (Biotechnology Prog)", 36 (2): e2936; Park et al., 2017, "Sci Rep (Sci Rep)", 10 (7): 44246) levels are 0.2ppm in mAb2 DS and 11.4ppm in mAb4 DS. In the enriched HMW, the abundance of TIMP1 was 3-13 times that in DS. β-Hexosaminidase, which has been reported to be associated with N-glycan degradation, was not detected in most mAb DS samples when present at levels of hundreds of ppm (Li et al., 2021, Progress in Biotechnology, 37(3): e3128), but its level in enriched HMW was increased. Other examples of frequently identified HCPs include keratin-A, peroxiredoxin, and complement C1r-A subcomponents, which were more abundant in enriched HMW than in DS.

[0311] Lipases are a group of problematic host cell proteins that may degrade polysorbates, thereby inducing aggregate formation and affecting the shelf life of the drug product (Chiu et al.; McShan et al.; Zhang et al. 2020; Zhang et al. 2021). Sialyl-O-acetylesterase, lipoprotein lipase, and other lipases were more abundant in enriched HMW than in DS, while PLBD2 was below the detection limit in all five mAbs and was present at trace levels in enriched HMW. Total lipase levels were below 3 ppm in all five mAbs, thus indicating that the purification process effectively removed this group of HCPs.

[0312] Protease enzymatic activity participates in proteolysis, and can induce the formation of small fragments, and affects product quality. The cathepsin L1 reported as the fragmentation of inducing mAb (Luo et al.) was detected in all five mAbs. The level of cathepsin L1 in the enriched HMW is significantly higher than the level in DS. It is worth noting that the level of cathepsin L1 in DS is lower than 0.8ppm in all mAb DS. For mAb2, carboxypeptidase (i.e., another protease that cuts both C-terminal lysine and arginine) is mainly detected in the enriched HMW. Cathepsin D (Bee et al., 2015, "Progress in Biotechnology", 31 (5): 1360-1369), which adversely affects product stability by causing mAb fragmentation and particle formation, is not detectable in DS and is lower than 0.3ppm in the enriched HMW.

[0313] Previous studies have shown that HCPs that escape multiple purification processes and are present in the final drug product are "hitch-hiker" proteins (Ranjan et al., 2019, "Biotechnology and Bioengineering", 116 (7): 1684-1697). These HCPs may have strong specific or nonspecific interactions with mAbs (Bee et al., 2017, "Progress in Biotechnology", 33 (1): 140-145), and based on their chemical properties, they cannot be removed by polishing steps. The present disclosure shows that because the abundance of HCPs in enriched HMW is significantly higher than that in DS, some HCPs are specifically or nonspecifically associated with mAb HMW species. In addition, these results show that the interaction between HCPs and HMW species is highly molecularly dependent because the abundance of the same HCP is different in different mAbs.

[0314] Example 9: Characterization of Host Cell Proteins in Enriched HMW

[0315] Determining which specific characteristics of HCPs may contribute to the enrichment of the high molecular weight fraction of a biotherapeutic product is important to inform process development. Fig.41B The predicted isoelectric point (pI) and molecular weight (MW) distribution of all HCPs in the analyzed enriched HMW for all five mAbs studied are shown in Fig.41AThe characteristics of HCPs from the DS of all five mAbs studied are compared. It is assumed that HCPs with high MW will co-elute with HMW mAb species. However, the MW of most HCPs enriched in the HMW fraction is between 10kDa and 100kDa, which is lower than the MW of mAb. Therefore, a large proportion of HCPs are retained in the HMW fraction due to the interaction with the HMW mAb species rather than their own size. The pI distribution of the HCPs identified from the HMW is comparable to that identified from the DS.

[0316] As previously mentioned, the CC motif chemokine was the most abundant in mAb2 relative to the HMW enriched at 46 times the abundance in the DS. The CC motif chemokine belongs to the chemokine family and plays a role in immune and inflammatory responses. Based on the known characteristics of this HCP and the measured abundance, it was determined that the relatively high level of the CC motif chemokine in the mAb2 DS may be a safety concern. The chemical properties of the CC motif chemokine and the detailed purification steps of mAb2 were reviewed to understand how this HCP was retained in the final DS.

[0317] The CC motif chemokine is a small HCP with a molecular weight of 15.8 kDa and an estimated pI of 9.16. The mAb is first purified by affinity chromatography, which captures the mAb and washes off process impurities, and can effectively remove HCPs that are not bound to the mAb or resin. In the following polishing step, the acidic HCPs in the protein A eluate will attach to the positively charged AEX ligand at neutral pH and be removed. Basic HCPs (such as CC motif chemokines) are positively charged at neutral pH and co-elute with mAb in the flow-through mode of AEX purification. In the HIC purification step, highly hydrophobic impurities will bind to the column, while CC motif chemokines may flow through with mAb. Therefore, in the case where the CC motif chemokine is present in the protein A eluate, it may not be effectively removed by conventional mAb purification steps based on its chemical properties. In the case of HCPs (such as CC motif chemokines), additional analysis and potentially additional purification steps may be required to optimize the production of biotherapeutic products.

[0318] Example 10: Comparison of CC motif chemokines in dimers, vHMWs and enriched HMWs from mAbl

[0319] The CC motif chemokine was more abundant in mAb2 than in the other products, thus suggesting that the presence of this HCP may be due to a specific interaction with mAb2 rather than the resin. Because the CC motif chemokine was significantly more abundant in the enriched HMW than in the DS, association may occur between the HMW species and this HCP. The HMW fraction contained heterogeneous species, including dimers and vHMW. To determine which specific HMW species were responsible for the interaction with the CC motif chemokine, further studies were investigated using additional SEC fractionation of mAb2.

[0320] The mAb2 enriched HMW was further fractionated using another round of SEC to obtain an enriched dimer fraction and an enriched vHMW fraction. The twenty most abundant HCPs identified from these three fractions are shown in Fig.42 HCPs are listed in order of abundance in the enriched HMWs of mAb 2. The heat map is colored by HCP level, ranging from 0 ppm (blue, not detected) to over 100 ppm (red).

[0321] A total of 123 HCPs were identified from the dimer fraction, compared to 110 and 102 HCPs in the enriched total HMW fraction and vHMW fraction, respectively. The CC motif chemokine abundance in all three HMW fractions was significantly higher than that in DS, and the levels were somewhat similar in each fraction. The concentrations of CC motif chemokines in the enriched vHMW fraction, total HMW fraction, and dimer fraction were 934.5ppm, 1738.5ppm, and 7733.9ppm, respectively. The level of CC motif chemokines in the dimer fraction was the highest, eight times the level in the enriched vHMW. At the same time, the CC motif chemokines in the enriched vHMW fraction were almost half of those in the enriched total HMW fraction. The findings indicate that CC motif chemokines are most likely to associate with dimers, rather than with vHMW species or total DS.

[0322] Except for CC motif chemokines, most of the detected HCPs (such as carboxypeptidases and β-hexosaminidase) were specifically enriched in the dimer fraction. Other HCPs (such as connective tissue growth factor) were significantly higher in the vHMW fraction than in the dimer fraction.

[0323] Example 11: SEC Fractionation and PRM Analysis

[0324] Since CC motif chemokines were enriched in the mAb2 HMW fraction, it was inferred that the removal of HMW species might help to clear this HCP from DS. To verify this hypothesis, mAb2 DS was fractionated by SEC. After SEC fractionation, HMW species, monomers, and LMW species were obtained, as shown in Figure 2. Fig.43 The SEC fractions as well as mAb2 DS were subjected to trypsin digestion and PRM analysis. The levels of CC motif chemokines were assessed by comparison with the levels of spiked internal standards. The distribution of CC motif chemokines in different fractions is shown in Fig.43 middle.

[0325] There are about 63.8fmol CC motif chemokines in the unfractionated DS. After SEC column purification, the level of CC motif chemokines in the monomer fraction was reduced to 2.4fmol, accounting for 3.2% of the total CC motif chemokines in the three fractions. Interestingly, the LMW fraction contained 25.3% of the CC motif chemokines, which can represent dissociated species. This finding indicates that under SEC conditions, the CC motif chemokines are partially dissociated and exist in an unbound form. The collected fraction volume of LMW is about six times the collected fraction volume of the monomer, and the CC motif chemokine level in LMW is about eight times the level in DS. The CC motif chemokines present in mAb2 DS may be a dissociated form after SEC fractionation. Despite the potential dissociation, most CC motif chemokine levels are significantly enriched in the HMW fraction, at 53.2fmol, or 71.5% of the total HCP.

[0326] These results suggest that HCPs (e.g. Fig.40 The CC motif chemokine in the mAb2 DS shown can be used with Fig.42 The HMW species shown (such as antibody dimers) have specific interactions and can therefore be enriched in the HMW fraction of DS. Using SEC and LC-MS / MS, the distribution and abundance of problematic HCPs can be assessed, the specific antibody species responsible for the undesirable interaction can be determined, and the problematic HCPs can be substantially removed from DS using SEC fractionation, such as Fig.43 Thus, the present disclosure provides a novel method for improving the production of biotherapeutic products by specifically removing HCPs that might otherwise lead to product instability or immunogenicity.

[0327] HMW species are product-related variants that may affect the efficacy and safety of therapeutic protein products. Immunogenicity assays have shown that aggregates induce immune responses to FVIII (Reipert et al., 2007, Br J Haematol, 136(1):12-15; Purohit and Balasubramanian, 2008, Journal of Pharmaceutical Sciences, 95(2):358-371), recombinant human growth hormone (Fradkin and Randolph, 2009, Journal of Pharmaceutical Sciences, 98(9):3247-3264) and IgG (Joubert et al., 2012, Journal of Biochemistry, 287(30):25266-25279). The mechanism by which HMW species cause immunogenicity remains unclear. The above studies indicate that high levels of HCPs may be present in the HMW fraction of biotherapeutic products DS. Therefore, in addition to or in place of HMW therapeutic protein species themselves, HCPs may also induce immunogenicity.

[0328] In this work, HCP analysis was performed on the HMW fraction separated by SEC. As with other chromatographic separation methods, SEC fractionation of HMW enables the detection of a greater number of HCPs. If appropriate, SEC can be incorporated as an alternative HCP enrichment strategy for HCP analysis to facilitate the detection of low-abundance HCPs. Unlike HILIC chromatography, which denatures HCPs under high organic gradients, SEC maintains the HCPs in their native state and readily binds to native digests. Therefore, detection sensitivity can be further improved by using native digests after HCP enrichment.

[0329] Studying the association between HCP and mAb is challenging because the level of HCP is very low relative to the level of drug product. Previous studies have applied cross-interaction chromatography (Levy et al., 2013, Biotechnology and Bioengineering, 111(5):904-912; Aboulaich et al., 2014, Biotechnology and Bioengineering, 30(5):1114-1124; Zhang et al., 2016, Biotechnology Progress, 32(3):708-717) or surface plasmon resonance (Bee et al. 2017) to determine the binding activity between mAb and HCP. The results described in this disclosure indicate that the association between HCP and HMW species can explain why some HCPs are co-purified with DS. Although the interaction mechanism remains unclear, these findings provide new directions for studying the association of mAb with HCP. More importantly, removing HMW species from DS can significantly reduce the levels of certain HCPs and provide information for promoting downstream purification process development. Therefore, the present disclosure of HCP profiling of HMW species expands the knowledge about HCPs present in mAb formulations and their interaction mechanisms, which helps to understand HMW species, immunogenicity, HCP identification and HCP removal for the comprehensive development of therapeutic protein drugs.

Claims

1. A method for identifying host cell protein (HCP) impurities in a sample, the method comprising: a) subjecting a sample comprising at least one protein of interest and at least one HCP impurity to size exclusion chromatography (SEC) analysis to produce fractions; as well as b) subjecting the fractions to LC-MS analysis to identify the at least one HCP impurity.

2. The method of claim 1, wherein the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

3. The method of claim 1, wherein the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg. The method according to claim 3 , wherein the amount of protein loaded onto the SEC column is about 10 mg.

5. The method of claim 1, wherein the mobile phase used for the SEC analysis comprises about 10 mM phosphate and about 150 mM NaCl. The method according to claim 1 , wherein the mobile phase used for the SEC analysis is a denaturing mobile phase. The method according to claim 1 , wherein the mobile phase used for the SEC analysis is a non-denaturing mobile phase.

8. The method of claim 6, wherein the mobile phase comprises acetonitrile, optionally wherein the concentration of acetonitrile is between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 10% v / v, about 15% v / v or about 20% v / v.

9. The method of claim 8, wherein the concentration of acetonitrile is about 20% v / v.

10. The method of claim 6, wherein the mobile phase comprises at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 6 mM and about 36 mM, about 12 mM, about 24 mM, or about 40 mM.

11. The method of claim 10, wherein the at least one surfactant is a detergent.

12. The method of claim 11, wherein the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof.

13. The method of claim 12, wherein the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is about 12 mM and the concentration of sodium lauroyl sarcosinate is about 12 mM.

14. The method of claim 1, wherein the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction.

15. The method of claim 14, wherein the fractions further comprise a tail fraction.

16. The method of claim 15, wherein the HMW fraction comprises between about 0.3 column volumes (CV) and about 5 milliabsorptance units (mAU) of eluent.

17. The method of claim 15, wherein the main fraction comprises eluate between about 5 mAU and about 40 mAU.

18. The method of claim 15, wherein the tail fraction comprises an eluate between about 40 mAU and about 10 mAU or between about 40 mAU and about 3 mAU.

19. The method of claim 15, wherein the LMW fraction comprises an eluent between about 10 mAU and about 1.1 CV or between about 3 mAU and about 1.1 CV.

20. The method of claim 1, further comprising subjecting the fractions to enzymatic digestion prior to the LC-MS analysis of step (b).

21. The method of claim 20, wherein the enzymatic digestion is a limited digestion.

22. The method of claim 20, wherein the enzymatic digestion is performed by contacting the fractions with trypsin.

23. The method of claim 20, wherein the enzymatic digestion is performed by contacting the fractions with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

24. The method of claim 23, wherein the ratio of enzyme to protein is about 1:

200.

25. The method of claim 1, further comprising subjecting the fraction to acid precipitation prior to the LC-MS analysis of step (b).

26. The method of claim 25, wherein the acid precipitation comprises contacting the fraction with about 1% trifluoroacetic acid.

27. The method of claim 1(b), wherein the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

28. The method of claim 1, wherein the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

29. A method for identifying host cell protein (HCP) impurities in a sample, the method comprising: a) subjecting a sample comprising at least one protein of interest and at least one HCP impurity to size exclusion chromatography (SEC) analysis to produce fractions, wherein a mobile phase for said SEC analysis comprises about 12 mM sodium lauroyl sarcosinate and about 12 mM sodium deoxycholate; b) subjecting the fraction to acid precipitation to produce a detergent-depleted fraction, wherein the acid precipitation comprises contacting the fraction with about 1% trifluoroacetic acid; c) subjecting the detergent-depleted fraction to buffer exchange to produce a buffer-exchanged fraction; d) subjecting the buffer exchanged fraction to limited digestion to produce a peptide digest, wherein the limited digestion comprises contacting the buffer exchanged fraction with trypsin at an enzyme to substrate ratio of between about 1:200 and about 1:2000; and e) subjecting the peptide digest to LC-MS analysis to identify the at least one HCP impurity.

30. The method of claim 29, wherein the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product.

31. The method of claim 29, wherein the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg.

32. The method of claim 29, wherein the amount of protein loaded onto the SEC column is about 10 mg.

33. The method of claim 29, wherein the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction.

34. The method of claim 33, wherein the fractions further comprise a tail fraction.

35. The method of claim 34, wherein the HMW fraction comprises between about 0.3 column volumes (CV) and about 5 milliabsorptance units (mAU) of eluent.

36. The method of claim 34, wherein the main fraction comprises eluate between about 5 mAU and about 40 mAU.

37. The method of claim 34, wherein the tail fraction comprises an eluate between about 40 mAU and about 10 mAU or between about 40 mAU and about 3 mAU.

38. The method of claim 34, wherein the LMW fraction comprises an eluent between about 10 mAU and about 1.1 CV or between about 3 mAU and about 1.1 CV.

39. The method of claim 29(e), wherein the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

40. The method of claim 29, wherein the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

41. A method for characterizing the binding of a host cell protein (HCP) impurity to a protein of interest, the method comprising: a) obtaining a sample comprising a protein of interest and at least one HCP impurity; b) subjecting the sample to size exclusion chromatography (SEC) analysis using a non-denaturing mobile phase to produce a primary fraction; c) subjecting the sample of (a) to SEC analysis using a denaturing mobile phase to produce a denatured fraction; d) subjecting the native fraction and the denatured fraction to LC-MS analysis to generate a native separation profile and a denatured separation profile of the at least one host cell protein impurity; as well as e) comparing the native separation profile to the denatured separation profile to characterize the binding of the at least one HCP impurity to the protein of interest.

42. The method of claim 41, wherein the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product.

43. The method of claim 41, wherein the amount of protein loaded onto the SEC column is between about 0.5 mg and about 20 mg, between about 1 mg and about 10 mg, between about 8 mg and about 12 mg, about 1 mg, about 5 mg, about 10 mg, or about 20 mg.

44. The method of claim 43, wherein the amount of protein loaded onto the SEC column is about 10 mg.

45. The method of claim 41, wherein the mobile phase comprises about 10 mM phosphate and about 150 mM NaCl.

46. ​​The method of claim 41, wherein the denaturing mobile phase is a mildly denaturing mobile phase.

47. The method of claim 41, wherein the denaturing mobile phase comprises acetonitrile, optionally wherein the concentration of acetonitrile is between about 5% v / v and about 20% v / v, between about 10% v / v and about 20% v / v, between about 15% v / v and about 20% v / v, about 5% v / v, about 10% v / v, about 15% v / v, or about 20% v / v.

48. The method of claim 47, wherein the concentration of acetonitrile is about 20% v / v.

49. The method of claim 41, wherein the fractions include a high molecular weight (HMW) fraction, a main fraction, and a low molecular weight (LMW) fraction.

50. The method of claim 49, wherein the fractions further comprise a tail fraction.

51. The method of claim 50, wherein the HMW fraction comprises between about 0.3 column volumes (CV) and about 5 milliabsorptivity units (mAU) of eluent.

52. The method of claim 50, wherein the main fraction comprises eluate between about 5 mAU and about 40 mAU.

53. The method of claim 50, wherein the tail fraction comprises an eluate between about 40 mAU and about 10 mAU or between about 40 mAU and about 3 mAU.

54. The method of claim 50, wherein the LMW fraction comprises an eluent between about 10 mAU and about 1.1 CV or between about 3 mAU and about 1.1 CV.

55. The method of claim 41, further comprising subjecting the fractions to enzymatic digestion prior to the LC-MS analysis of step (d).

56. The method of claim 55, wherein the enzymatic digestion is a limited digestion.

57. The method of claim 55, wherein the enzymatic digestion is performed by contacting the fractions with trypsin.

58. The method of claim 55, wherein the enzymatic digestion is performed by contacting the fractions with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

59. The method of claim 58, wherein the ratio of enzyme to protein is about 1:

200.

60. The method of claim 41(d), wherein the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

61. The method of claim 41, wherein the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

62. A method for identifying host cell protein (HCP) impurities in a sample, the method comprising: a) combining a sample comprising at least one protein of interest and at least one HCP impurity with a dissociation reagent to produce a first combination; b) subjecting said first combination to acid precipitation to produce a fraction depleted of dissociation reagent; as well as c) subjecting the dissociation reagent depleted fraction to liquid chromatography-mass spectrometry analysis to identify the at least one HCP impurity.

63. The method of claim 62, wherein the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product.

64. The method of claim 62, wherein the sample is incubated in the dissociation reagent for about 5 minutes to about 120 minutes, about 15 minutes, about 30 minutes, about 60 minutes, or about 120 minutes.

65. The method of claim 64, wherein the dissociation reagent comprises at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM or about 120 mM.

66. The method of claim 65, wherein the at least one surfactant is a detergent.

67. The method of claim 66, wherein the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof.

68. The method of claim 66, wherein the at least one detergent is sodium lauroyl sarcosinate, wherein the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

69. The method of claim 66, wherein the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM, and the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

70. The method of claim 66, wherein the at least one detergent is sodium deoxycholate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

71. The method of claim 66, further comprising subjecting the dissociation agent-depleted fraction to enzymatic digestion to produce a peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (c).

72. The method of claim 71, wherein the enzymatic digestion is a limited digestion.

73. The method of claim 71, wherein the enzymatic digestion is performed by contacting the dissociation reagent-depleted fraction with trypsin.

74. The method of claim 71, wherein the enzymatic digestion is performed by contacting the dissociation reagent-depleted fraction with a digestive enzyme at an enzyme to protein ratio of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

75. The method of claim 74, wherein the ratio of enzyme to protein is about 1:

200.

76. The method of claim 71, further comprising desalting the peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (c).

77. The method of claim 62, wherein the acid precipitation is incubated for about 5 minutes to about 60 minutes, about 5 minutes, or about 60 minutes.

78. The method of claim 77, wherein the acid precipitation comprises contacting the first combination with about 2.5% to about 10% trifluoroacetic acid, about 2.5% trifluoroacetic acid, about 5% trifluoroacetic acid, about 7.5% trifluoroacetic acid, or about 10% trifluoroacetic acid.

79. The method of claim 62, wherein the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

80. The method of claim 62, wherein the mass spectrometer is an electrospray ionization mass spectrometer, a nanoelectrospray ionization mass spectrometer, or an Orbitrap-based mass spectrometer, wherein the mass spectrometer is coupled to the liquid chromatography system.

81. A method for identifying host cell protein (HCP) impurities in a sample, the method comprising: a) combining a sample comprising at least one protein of interest and at least one HCP impurity with a dissociation reagent to produce a first combination; b) subjecting said first combination to acid precipitation to produce a fraction depleted of dissociation reagent; c) subjecting the dissociation reagent-depleted fraction to buffer exchange to produce a buffer-exchanged fraction; d) subjecting the buffer exchanged fraction to enzymatic digestion to produce a peptide digest; as well as e) subjecting the peptide digest to liquid chromatography-mass spectrometry analysis to identify the at least one HCP impurity.

82. The method of claim 81, wherein the at least one protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product.

83. The method of claim 81, wherein the dissociation reagent is at least one surfactant, optionally wherein the concentration of the at least one surfactant is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM or about 120 mM.

84. The method of claim 83, wherein the at least one surfactant is a detergent.

85. The method of claim 84, wherein the at least one detergent is selected from the group consisting of sodium deoxycholate, sodium lauroyl sarcosinate, and combinations thereof.

86. The method of claim 85, wherein the first combination is incubated for about 5 minutes to about 120 minutes, about 5 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes prior to the acid precipitation of step (b).

87. The method of claim 84, wherein the at least one detergent is sodium lauroyl sarcosinate, wherein the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

88. The method of claim 84, wherein the at least one detergent is sodium deoxycholate and sodium lauroyl sarcosinate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM, and the concentration of sodium lauroyl sarcosinate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

89. The method of claim 84, wherein the at least one detergent is sodium deoxycholate, wherein the concentration of sodium deoxycholate is between about 20 mM and about 120 mM, about 20 mM, about 40 mM, about 60 mM, about 100 mM, or about 120 mM.

90. The method of claim 81, wherein the enzymatic digestion is a limited digestion.

91. The method of claim 81, wherein the enzymatic digestion is performed by contacting the fractions with trypsin.

92. The method of claim 81, wherein the enzymatic digestion is performed by contacting the fractions with a digestive enzyme at a ratio of enzyme to protein of between about 1:100 and about 1:2000, between about 1:200 and about 1:2000, about 1:100, about 1:200, about 1:300, about 1:400, about 1:500, about 1:1000, or about 1:2000.

93. The method of claim 92, wherein the ratio of enzyme to protein is about 1:

200.

94. The method of claim 81, further comprising desalting the peptide digest prior to the liquid chromatography-mass spectrometry analysis of step (e).

95. The method of claim 81, wherein the acid precipitation is incubated for about 5 minutes to about 60 minutes, about 5 minutes, or about 60 minutes.

96. The method of claim 81, wherein the acid precipitation comprises contacting the first combination with about 2.5% to about 10% trifluoroacetic acid, about 2.5% trifluoroacetic acid, about 5% trifluoroacetic acid, about 7.5% trifluoroacetic acid, or about 10% trifluoroacetic acid.

97. The method of claim 81, wherein the liquid chromatography comprises reverse phase liquid chromatography, ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

98. A method for preparing a biotherapeutic product, the method comprising: (a) subjecting a first sample comprising at least one protein of interest and at least one host cell protein (HCP) impurity to size exclusion chromatography (SEC) analysis to produce a plurality of fractions; (b) subjecting the plurality of fractions to liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis to determine the identity and amount of the at least one HCP impurity; (c) using the identity and the amount to determine whether the at least one HCP impurity is a relevant impurity of at least one of the plurality of fractions; (d) subjecting a second sample comprising the at least one protein of interest and the at least one HCP impurity to SEC analysis to produce a second plurality of fractions; as well as (e) using the determination of step (c), removing from the plurality of fractions of step (d) the at least one fraction in which the at least one HCP impurity is an impurity of interest to produce a biotherapeutic product.

99. The method of claim 98, wherein the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein pharmaceutical product.

100. The method of claim 98, wherein the mobile phase of the SEC analysis comprises about 150 mM ammonium acetate.

101. The method of claim 98, wherein the at least one HCP impurity comprises a lipase, a protease, or a combination thereof.

102. The method of claim 98, wherein the at least one HCP impurity comprises a CC motif chemokine.

103. The method of claim 98, wherein the plurality of fractions comprises a high molecular weight (HMW) fraction, a very high molecular weight (vHMW) fraction, a dimer fraction, a monomer fraction, a low molecular weight (LMW) fraction, a tail fraction, or a combination thereof.

104. The method of claim 98, wherein the at least one HCP impurity is a fraction of an impurity of interest is a HMW fraction.

105. The method of claim 98, wherein the at least one HCP impurity is present in the fraction at about 1000 parts per million (1000 ppm) to about 10000 ppm, about 1000 ppm, about 2000 ppm, about 3000 ppm, about 4000 ppm, about 5000 ppm, about 6000 ppm, about 7000 ppm, about 8000 ppm, about 9000 ppm, or about 10000 ppm.

106. The method of claim 98, wherein the percentage of at least one HCP impurity enriched in the HMW fraction is between about 30% and about 100%, being about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100%.

107. The method of claim 98, further comprising subjecting the sample of (a) to native digestion prior to SEC analysis.

108. The method of claim 107, wherein the native digestion is limited digestion.

109. The method of claim 107, wherein the native digestion is performed by contacting the sample with trypsin.

110. The method of claim 98, wherein the LC-MS / MS analysis comprises reverse phase liquid chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, strong cation exchange chromatography, size exclusion chromatography, affinity chromatography, protein A chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.

111. The method of claim 98, wherein the LC-MS / MS analysis comprises parallel reaction monitoring.

112. A method for preparing a biotherapeutic product, the method comprising: A sample comprising a protein of interest, at least one HMW species, and at least one HCP impurity is subjected to one or more chromatography steps that reduce the abundance of the at least one HCP impurity, wherein the at least one HCP impurity interacts with the at least one HMW species.

113. The method of claim 112, wherein the interaction of the at least one HCP impurity with the at least one HMW species can be identified by enriching the at least one HMW species.

114. The method of claim 113, wherein the enriching comprises subjecting the sample comprising the at least one HMW species and the at least one HCP impurity to SEC.

115. The method of claim 114, further comprising subjecting the at least one HMW species and the at least one HCP impurity to buffer exchange, native digestion, denaturation, molecular weight filtration, one or more additional chromatography steps and / or mass spectrometry analysis.

116. The method of claim 112, wherein the protein of interest is an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug product.

117. The method of claim 112, wherein the at least one HCP impurity comprises a lipase, a protease, or a combination thereof.

118. The method of claim 112, wherein the at least one HCP impurity comprises a CC motif chemokine.

119. The method of claim 112, wherein the at least one HMW species comprises a dimer, an aggregate, or a combination thereof.

120. The method of claim 112, wherein the one or more chromatography steps comprise reverse phase liquid chromatography, ion exchange chromatography, anion exchange chromatography, cation exchange chromatography, strong cation exchange chromatography, size exclusion chromatography, affinity chromatography, protein A chromatography, hydrophobic interaction chromatography, hydrophilic interaction chromatography, mixed mode chromatography, or a combination thereof.